{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# LLM Agents for Clinical Trial Management - Patient Evaluation Workflow\n",
    "\n",
    "In this notebook, we demonstrate how an agent-based Large Language Model (LLM) can be applied to automate the evaluation of patients for potential clinical trials. \n",
    "By utilizing documents related to patient medical histories, clinical policies, and trial inclusion criteria, this notebook illustrates the end-to-end process of assessing patient eligibility.\n",
    "\n",
    "**Objective**: Showcase the implementation of clinical trial data management, compliance verification, and automated matching of patients to suitable trials using advanced LLM techniques.\n",
    "\n",
    "### Key Processes Covered in this Notebook:\n",
    "1. **Data Collection and Preprocessing**: Importing and preparing patient data.\n",
    "2. **Patient Profile Analysis**: Using LLMs to analyze patient data and extract relevant information.\n",
    "3. **Eligibility Verification**: Assessing patient data against clinical trial policies to determine eligibility.\n",
    "4. **Trial Matching**: Utilizing agentic workflows to identify suitable trials for patients.\n",
    "5. **Hallucination Prevention**: Using a hallucination grader to ensure model outputs are contextually accurate.\n",
    "\n",
    "### Note\n",
    "This notebook uses simplified demo data for the purpose of illustrating the capabilities of an LLM-driven agentic pipeline. For production-level implementation, clinical expertise, comprehensive datasets, and advanced tools (e.g., advanced Retrieval-Augmented Generation (RAG)) are required.\n",
    "\n",
    "Let's get started by setting up the environment and importing the necessary libraries.\n",
    "\n",
    "## Visual Representation of the Pipeline:\n",
    "<image src=\"../images/diagram.png\" alt=\"Pipeline Diagram\" width=\"800\"/>"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Loading libraries"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "USER_AGENT environment variable not set, consider setting it to identify your requests.\n"
     ]
    }
   ],
   "source": [
    "%load_ext autoreload\n",
    "%autoreload 2\n",
    "import getpass\n",
    "import os\n",
    "import pandas as pd\n",
    "from langchain.text_splitter import RecursiveCharacterTextSplitter\n",
    "from langchain_community.document_loaders import WebBaseLoader\n",
    "from langchain_community.vectorstores import Chroma\n",
    "from langchain_nomic.embeddings import NomicEmbeddings\n",
    "from langchain_community.document_loaders import UnstructuredMarkdownLoader\n",
    "from langchain_core.documents import Document\n",
    "import chromadb\n",
    "\n",
    "from dotenv import load_dotenv, find_dotenv\n",
    "load_dotenv(find_dotenv())\n",
    "\n",
    "def _set_if_undefined(var: str):\n",
    "    if not os.environ.get(var):\n",
    "        os.environ[var] = getpass.getpass(f\"Please provide your {var}\")\n",
    "\n",
    "# Loading the requied environment variables\n",
    "_set_if_undefined(\"OPENAI_API_KEY\")\n",
    "_set_if_undefined(\"LANGCHAIN_API_KEY\")\n",
    "\n",
    "# Optional, add tracing in LangSmith\n",
    "os.environ[\"LANGCHAIN_TRACING_V2\"] = \"true\"\n",
    "os.environ[\"LANGCHAIN_PROJECT\"] = \"Clinical Trial Management\""
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Parameters"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Using Groq model: gemma2-9b-it\n"
     ]
    }
   ],
   "source": [
    "from langchain_openai import ChatOpenAI\n",
    "from langchain_groq import ChatGroq\n",
    "\n",
    "free_model = True\n",
    "\n",
    "policy_vstore_created = False\n",
    "trials_vstore_created = False\n",
    "trials_db_downloaded = False\n",
    "trials_path = \"../data/trials_data.csv\" \n",
    "\n",
    "DEBUG = False\n",
    "\n",
    "chromadb_path = \"../chroma_db\"\n",
    "policy_collection = \"policy-chroma\"\n",
    "trial_collection = \"trial-chroma\"\n",
    "\n",
    "# OpenAI models\n",
    "modelID = \"gpt-3.5-turbo\"\n",
    "modelID_agent = \"gpt-4o\"\n",
    "# modelID_agent = \"gpt-3.5-turbo\"\n",
    "\n",
    "# Groq models\n",
    "modelID_groq = \"gemma2-9b-it\"\n",
    "# modelID_groq = \"llama-3.1-8b-instant\"\n",
    "# modelID_groq = \"mistral-saba-24b\"\n",
    "# modelID_groq_agent = \"llama-3.3-70b-versatile\"\n",
    "modelID_groq_agent = modelID_groq\n",
    "\n",
    "\n",
    "n_retrieved_policies = 5 # Number of most relevant policies to retrieve per patient\n",
    "n_retrieved_trials = 6\n",
    "\n",
    "if free_model:    \n",
    "    model = ChatGroq(model=modelID_groq, temperature=0)\n",
    "    model_agent = ChatGroq(model=modelID_groq_agent, temperature=0)\n",
    "    print(f\"Using Groq model: {modelID_groq}\")\n",
    "else:\n",
    "    model = ChatOpenAI(temperature = 0.0, model=modelID)\n",
    "    model_agent = ChatOpenAI(temperature=0, model=modelID_agent)\n",
    "    print(f\"Using OpenAI model: {modelID}\")\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "import warnings\n",
    "warnings.filterwarnings(\"ignore\")\n",
    "\n",
    "import pprint\n",
    "# A function for printing nicely\n",
    "def nprint(text, indent=2):\n",
    "    pp = pprint.PrettyPrinter(indent=indent)\n",
    "    pp.pprint(text)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Creating the demo datasets"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Patients database\n",
    "\n",
    "We create a sample dataset of patients with their medical history, previous trials, and other relevant information.   \n",
    "We use random names, diseases, and past or ongoing trials.  \n",
    "This is a demo dataset limited information. However, for real cases, a more complit medical history of patients will be used."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Demo patient database created at: /Users/bobhosseini/Portfolio/llm_pharma/sql_server/patients.db\n",
      "CSV export created at: /Users/bobhosseini/Portfolio/llm_pharma/data/patients.csv\n",
      "Total patients created: 100\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>patient_id</th>\n",
       "      <th>name</th>\n",
       "      <th>age</th>\n",
       "      <th>medical_history</th>\n",
       "      <th>previous_trials</th>\n",
       "      <th>trial_status</th>\n",
       "      <th>trial_completion_date</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>1</td>\n",
       "      <td>Sophia Martinez</td>\n",
       "      <td>72</td>\n",
       "      <td>Hypertension</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2</td>\n",
       "      <td>James Johnson</td>\n",
       "      <td>44</td>\n",
       "      <td>ovarian cancer</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>3</td>\n",
       "      <td>Oliver Martinez</td>\n",
       "      <td>60</td>\n",
       "      <td>colorectal cancer</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>4</td>\n",
       "      <td>Oliver Garcia</td>\n",
       "      <td>76</td>\n",
       "      <td>Heart Disease</td>\n",
       "      <td>NCT01609160</td>\n",
       "      <td>Withdrawn</td>\n",
       "      <td>2024-02-11</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>5</td>\n",
       "      <td>Daniel Thomas</td>\n",
       "      <td>73</td>\n",
       "      <td>soft tissue sarcoma</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   patient_id             name  age      medical_history previous_trials  \\\n",
       "0           1  Sophia Martinez   72         Hypertension                   \n",
       "1           2    James Johnson   44       ovarian cancer                   \n",
       "2           3  Oliver Martinez   60    colorectal cancer                   \n",
       "3           4    Oliver Garcia   76        Heart Disease     NCT01609160   \n",
       "4           5    Daniel Thomas   73  soft tissue sarcoma                   \n",
       "\n",
       "  trial_status trial_completion_date  \n",
       "0                                     \n",
       "1                                     \n",
       "2                                     \n",
       "3    Withdrawn            2024-02-11  \n",
       "4                                     "
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# import os\n",
    "import sqlite3\n",
    "import sys\n",
    "sys.path.append('/Users/bobhosseini/Portfolio/llm_pharma')\n",
    "from backend.helper_functions import create_demo_patient_database\n",
    "database_file = \"sql_server/patients.db\"\n",
    "df = create_demo_patient_database(database_file)\n",
    "df.head()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Creating a local SQLite database for patients"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "100\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>patient_id</th>\n",
       "      <th>name</th>\n",
       "      <th>age</th>\n",
       "      <th>medical_history</th>\n",
       "      <th>previous_trials</th>\n",
       "      <th>trial_status</th>\n",
       "      <th>trial_completion_date</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>1</td>\n",
       "      <td>Sophia Martinez</td>\n",
       "      <td>72</td>\n",
       "      <td>Hypertension</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2</td>\n",
       "      <td>James Johnson</td>\n",
       "      <td>44</td>\n",
       "      <td>ovarian cancer</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>3</td>\n",
       "      <td>Oliver Martinez</td>\n",
       "      <td>60</td>\n",
       "      <td>colorectal cancer</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>4</td>\n",
       "      <td>Oliver Garcia</td>\n",
       "      <td>76</td>\n",
       "      <td>Heart Disease</td>\n",
       "      <td>NCT01609160</td>\n",
       "      <td>Withdrawn</td>\n",
       "      <td>2024-02-11</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>5</td>\n",
       "      <td>Daniel Thomas</td>\n",
       "      <td>73</td>\n",
       "      <td>soft tissue sarcoma</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>6</td>\n",
       "      <td>Emily Johnson</td>\n",
       "      <td>75</td>\n",
       "      <td>myeloma</td>\n",
       "      <td>NCT01683974</td>\n",
       "      <td>Ongoing</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>7</td>\n",
       "      <td>Sophia Anderson</td>\n",
       "      <td>74</td>\n",
       "      <td>myelomonocytic leukemia</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>8</td>\n",
       "      <td>Alice Johnson</td>\n",
       "      <td>78</td>\n",
       "      <td>mesothelioma</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>9</td>\n",
       "      <td>John Brown</td>\n",
       "      <td>27</td>\n",
       "      <td>Arthritis</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>10</td>\n",
       "      <td>Emily Smith</td>\n",
       "      <td>40</td>\n",
       "      <td>myeloma</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   patient_id             name  age          medical_history previous_trials  \\\n",
       "0           1  Sophia Martinez   72             Hypertension                   \n",
       "1           2    James Johnson   44           ovarian cancer                   \n",
       "2           3  Oliver Martinez   60        colorectal cancer                   \n",
       "3           4    Oliver Garcia   76            Heart Disease     NCT01609160   \n",
       "4           5    Daniel Thomas   73      soft tissue sarcoma                   \n",
       "5           6    Emily Johnson   75                  myeloma     NCT01683974   \n",
       "6           7  Sophia Anderson   74  myelomonocytic leukemia                   \n",
       "7           8    Alice Johnson   78             mesothelioma                   \n",
       "8           9       John Brown   27                Arthritis                   \n",
       "9          10      Emily Smith   40                  myeloma                   \n",
       "\n",
       "  trial_status trial_completion_date  \n",
       "0                                     \n",
       "1                                     \n",
       "2                                     \n",
       "3    Withdrawn            2024-02-11  \n",
       "4                                     \n",
       "5      Ongoing                        \n",
       "6                                     \n",
       "7                                     \n",
       "8                                     \n",
       "9                                     "
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "conn = sqlite3.connect('../' + database_file)\n",
    "cursor = conn.cursor()\n",
    "\n",
    "query = 'SELECT * FROM patients'\n",
    "\n",
    "# Execute the query and fetch all results\n",
    "cursor.execute(query)\n",
    "rows = cursor.fetchall()\n",
    "\n",
    "# Optionally, you can get the column names\n",
    "column_names = [description[0] for description in cursor.description]\n",
    "\n",
    "# Convert the results to a Pandas DataFrame for better readability\n",
    "df = pd.DataFrame(rows, columns=column_names)\n",
    "print(len(df))\n",
    "\n",
    "# Display the DataFrame\n",
    "conn.close()\n",
    "\n",
    "db = database_file\n",
    "df.head(10)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Clinical Trials database\n",
    "\n",
    "We download a sample clinical trials database from a [publicly available source]('https://raw.githubusercontent.com/futianfan/clinical-trial-outcome-prediction/main/data/raw_data.csv').   \n",
    "Details are provided in the [helper function](../../src/helper_functions.py)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Trials database already downloaded and stored in ../data/trials_data.csv\n",
      "---- Sample 1 ----\n",
      "\n",
      "        Key Inclusion Criteria Core Phase:\n",
      "\n",
      "          -  diagnosis of multiple sclerosis\n",
      "\n",
      "          -  at least one MS relapse during the previous year or two MS relapses in the previous 2\n",
      "             years or evidence of Gd enhancing lesions on MRI within 6 months EDSS score of 0 to\n",
      "             5.5, inclusive\n",
      "\n",
      "        Key Exclusion Criteria Core Phase:\n",
      "\n",
      "          -  patients with progressive MS\n",
      "\n",
      "          -  patients with an active, chronic disease of the immune system other than MS\n",
      "\n",
      "          -  patients meeting the definition of ADEM\n",
      "\n",
      "          -  patients with severe cardiac disease or significant findings on the screening ECG.\n",
      "\n",
      "          -  patients with severe renal insufficiency\n",
      "\n",
      "        Key Inclusion Criteria Extension Phase:\n",
      "\n",
      "        Applies to all patients participating in the Core Phase and then entering the Extension\n",
      "        Phase. 1. Patients that originally met Core Phase Inclusion criteria and completed the Core\n",
      "        phase on or off of study drug.\n",
      "\n",
      "        Applies to patients newly recruited to participate in the Extension Phase.\n",
      "\n",
      "          -  All newly recruited patients' that enroll directly into the Extension Phase must\n",
      "             fulfill the local country health authority product label approved for pediatric age\n",
      "             group for inclusion criteria.\n",
      "\n",
      "          -  Central review (including initial MRI report) of the diagnosis of pediatric MS will be\n",
      "             required for all newly recruited patients.\n",
      "\n",
      "        Key Exclusion Criteria Extension Phase:\n",
      "\n",
      "        Applies to patients who completed the Core Phase, but prematurely discontinued study drug.\n",
      "\n",
      "          1. Premature discontinuation of the study drug during the Core Phase due to:\n",
      "\n",
      "               -  an adverse event,\n",
      "\n",
      "               -  serious adverse event,\n",
      "\n",
      "               -  laboratory abnormality\n",
      "\n",
      "               -  other conditions leading to permanent study drug discontinuation due to safety\n",
      "                  reasons\n",
      "\n",
      "          2. Patients with known new events or concomitant medications (washout periods required\n",
      "             prior to Visit 15) that would exclude them from the Core Phase exclusion criteria.\n",
      "             Serological or other additional tests will not be required.\n",
      "\n",
      "        Applies to patients newly recruited in the younger cohort to participate in the Extension\n",
      "        Phase.\n",
      "\n",
      "        1. All newly recruited patients in the younger cohort that enroll directly into the\n",
      "        Extension Phase must fulfill the exclusion criteria for the core phase.\n",
      "      \n",
      "---- Sample 2 ----\n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Subject is at least 20 years of age.\n",
      "\n",
      "          2. Written and voluntary informed consent understood, signed and dated.\n",
      "\n",
      "          3. They must have refractory or progressive colorectal cancer for which there is no\n",
      "             further curative therapy available.\n",
      "\n",
      "          4. Subject able to adhere to the study visit schedule and other protocol requirements.\n",
      "\n",
      "          5. ECOG 0-2\n",
      "\n",
      "          6. At least one measurable lesion that can be accurately assessed by imaging or physical\n",
      "             examination at baseline and following up visits.\n",
      "\n",
      "          7. Must have a life expectancy of 3 months or more\n",
      "\n",
      "          8. Demonstrate adequate organ function\n",
      "\n",
      "          9. Negative urine or serum pregnancy test within 28 days of study treatment\n",
      "\n",
      "         10. Be willing to provide fresh tissue for biomarker analysis, and, based on the adequacy\n",
      "             of the tissue sample quality for assessment of biomarker status.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. ECOG ≥ 3\n",
      "\n",
      "          2. History of malignancy in the last 5 years.\n",
      "\n",
      "          3. Subject has known historical or active infection with HIV, hepatitis B, or hepatitis\n",
      "             C.\n",
      "\n",
      "          4. Breast-feeding or pregnant female\n",
      "\n",
      "          5. Patients can not the administration of Folic acid or Vitamin B12.\n",
      "\n",
      "          6. Before treatment with Pemetrexed.\n",
      "\n",
      "          7. Patients who can not swallow oral medication.\n",
      "\n",
      "          8. The most recent treatment with the clinical trial for the drug for 14 days prior to\n",
      "             enrollment.\n",
      "\n",
      "          9. Systemic chemotherapy within three weeks after the administration of the last before\n",
      "             the test treatment, radiation therapy patients who had been administered.\n",
      "\n",
      "         10. Except for the hair loss, it is induced before cancer treatment, all of toxicity in\n",
      "             progress (> CTCAE1 grade).\n",
      "\n",
      "         11. Upper GI bleeding within registration before 4 weeks of Bowel obstruction or CTCAE3 or\n",
      "             4 grade.\n",
      "\n",
      "         12. Subject who experienced a recent myocardial infarction, including severe/unstable\n",
      "             angina pectoris, coronary/peripheral artery bypass graft, uncontrolled hypertension,\n",
      "             clinically significant cardiac dysrhythmia or clinically significant electrocardiogram\n",
      "             (ECG) abnormality, significant or uncontrolled cardiovascular disease CHF, and\n",
      "             cerebrovascular accident or transient ischemic attack, or seizure disorder in the past\n",
      "             year.\n",
      "      \n"
     ]
    }
   ],
   "source": [
    "import sys\n",
    "module_dir = os.path.abspath('../backend')  # Gets the absolute path to the src directory\n",
    "sys.path.append(module_dir)\n",
    "from helper_functions import dataset_create_trials\n",
    "\n",
    "overwrite = False\n",
    "trials_db_downloaded = True\n",
    "if trials_db_downloaded and not overwrite:\n",
    "    print(f'Trials database already downloaded and stored in {trials_path}')\n",
    "    df_trials = pd.read_csv(trials_path)\n",
    "    import ast\n",
    "    df_trials['diseases'] = df_trials['diseases'].apply(ast.literal_eval)\n",
    "    # df_trials['drugs'] = df_trials['drugs'].apply(ast.literal_eval)\n",
    "else:\n",
    "    df_trials, trials_path = dataset_create_trials(status='recruiting')\n",
    "    trials_db_downloaded = True\n",
    "\n",
    "# print the ctriteria column value froom 4 random rows of the dataferam. use a for loop\n",
    "df_samples = df_trials.sample(4).reset_index(drop=True)\n",
    "for i in range(2):\n",
    "    print(f'---- Sample {i+1} ----')\n",
    "    print(df_samples.iloc[i]['criteria'])\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Creating Vectore Stores"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Vstore for policy database\n",
    "\n",
    "To create a vector store for the policy database, we will use perform local embedding via NomicEmbeddings.   \n",
    "Also, to treat each policy separately, we split the policies main document into per policy chunks.   \n",
    "Note that this is a problem specific strategy, and may not be appropriate for all RAG applications."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "12\n",
      "No existing vectorstore\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Embedding texts: 100%|██████████| 12/12 [00:00<00:00, 57.58inputs/s]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Vectore store created and stored in persistent chromadb client\n",
      "24\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "Document(metadata={'source': '../source_data/instut_trials_policy.md'}, page_content='\\n#### 1. **General Eligibility Criteria**\\n   - **Age Restrictions**: Patients must be between 18 and 75 years old.\\n   - **Gender**: No restrictions unless specified by the trial protocol.\\n   - **Informed Consent**: All patients must provide informed consent prior to participation.\\n   - **Residency**: Patients must be residents of the country where the trial is conducted.\\n   - **Health Insurance**: Patients must have valid health insurance coverage.\\n')"
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import re\n",
    "\n",
    "# from langchain.text_splitter import RecursiveCharacterTextSplitter\n",
    "# from langchain_community.document_loaders import WebBaseLoader\n",
    "# from langchain_community.vectorstores import Chroma\n",
    "# from langchain_nomic.embeddings import NomicEmbeddings\n",
    "# from langchain_community.document_loaders import UnstructuredMarkdownLoader\n",
    "# from langchain_core.documents import Document\n",
    "# import chromadb\n",
    "\n",
    "vstore_load = False # change to True to load existing vectorstore\n",
    "markdown_path = \"../source_data/instut_trials_policy.md\"\n",
    "\n",
    "with open(markdown_path, \"r\") as f:\n",
    "    policy_text = f.read()\n",
    "\n",
    "\n",
    "doc_splits = [\n",
    "    Document(page_content= txt, metadata={\"source\": markdown_path}) for txt in re.split(r\"(?=\\n###)\", policy_text)\n",
    "    ]\n",
    "\n",
    "# the title of markdown is not required in the split\n",
    "doc_splits = doc_splits[1:]    \n",
    "\n",
    "print(len(doc_splits))\n",
    "doc_splits\n",
    "\n",
    "persistent_client = chromadb.PersistentClient(path = chromadb_path)\n",
    "\n",
    "if vstore_load == False:\n",
    "    try:\n",
    "        vectorstore.delete_collection()\n",
    "        print('Vectore store deleted')\n",
    "    except:\n",
    "        print('No existing vectorstore')\n",
    "\n",
    "if os.path.exists(chromadb_path) and vstore_load:     \n",
    "    vectorstore = Chroma(\n",
    "        client=persistent_client,\n",
    "        collection_name=policy_collection,\n",
    "        embedding_function=NomicEmbeddings(model=\"nomic-embed-text-v1.5\",\n",
    "                                inference_mode='local'),\n",
    "    )\n",
    "    print('Vectore store loaded from existing chromadb')\n",
    "else:\n",
    "    vectorstore = Chroma.from_documents(\n",
    "        documents=doc_splits,\n",
    "        client=persistent_client,\n",
    "        collection_name=policy_collection,\n",
    "        # persist_directory=chromadb_path,\n",
    "        embedding=NomicEmbeddings(model=\"nomic-embed-text-v1.5\",\n",
    "                                inference_mode='local'),\n",
    "    )\n",
    "    print('Vectore store created and stored in persistent chromadb client')\n",
    "\n",
    "print(vectorstore._collection.count())\n",
    "doc_splits[0]\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Vstore for trials"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "For simplicy, we just work on 3 main categories of cancer, lukemia, and mental health problems.   \n",
    "This selection gives us a managable set of trials as a demo application.   \n",
    "However, for a more proper application, categories can be extended with the help of domain specialists.\n",
    "\n",
    "The vectore store is created using chromadb and as a persistent client."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Collection trial-chroma is deleted\n",
      "/Users/bobhosseini/Portfolio/llm_pharma/data/trials_data.csv\n",
      "loaded trials: 30\n",
      "✅ Filtered trials to status 'recruiting': 30 trials\n",
      "sample trial doc metadata:\n",
      " {'nctid': 'NCT00715611', 'status': 'recruiting', 'diseases': \"['mesothelioma']\", 'disease_category': 'cancer', 'drugs': \"['pemetrexed and cisplatin or carboplatin']\"}\n",
      "removing trial 3 because it's for other conditions\n",
      "removing trial 4 because it's for other conditions\n",
      "removing trial 9 because it's for other conditions\n",
      "removing trial 11 because it's too long\n",
      "removing trial 12 because it's for other conditions\n",
      "removing trial 14 because it's for other conditions\n",
      "removing trial 16 because it's for other conditions\n",
      "removing trial 17 because it's for other conditions\n",
      "removing trial 18 because it's for other conditions\n",
      "removing trial 23 because it's for other conditions\n",
      "removing trial 25 because it's for other conditions\n",
      "removing trial 27 because it's for other conditions\n",
      "Number of trial docs to be added to the vector store: 18\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Embedding texts: 100%|██████████| 18/18 [00:02<00:00,  8.37inputs/s]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "✅ Trial vector store created with 18 trials\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\n"
     ]
    }
   ],
   "source": [
    "from helper_functions import create_trial_vectorstore\n",
    "\n",
    "vectorstore_trials = create_trial_vectorstore(\n",
    "    trials_csv_path='data/trials_data.csv',\n",
    "    vectorstore_path=chromadb_path,\n",
    "    collection_name=trial_collection,\n",
    "    status_filter=\"recruiting\",\n",
    "    vstore_delete=True\n",
    ")\n",
    "# vectorstore_trials._coll\n",
    "# from helper_functions import disease_map\n",
    "# from langchain_core.documents import Document\n",
    "\n",
    "# vstore_delete = False\n",
    "# print(f\"total trials: {len(df_trials)}\")\n",
    "\n",
    "# trial_docs = []\n",
    "# for i, row in df_trials.iterrows():\n",
    "#     disease = disease_map(row['diseases'])\n",
    "#     if disease == 'other_conditions':\n",
    "#         continue\n",
    "#     doc = Document(\n",
    "#         page_content=row['criteria'],\n",
    "#         metadata={\n",
    "#             \"nctid\": row['nctid'],\n",
    "#             \"status\": row['status'],\n",
    "#             # \"why_stop\": row['why_stop'],\n",
    "#             # \"label\": row['label'],\n",
    "#             # \"phase\": row['phase'],\n",
    "#             \"diseases\": str(row['diseases']),\n",
    "#             \"disease_category\": disease[0],\n",
    "#             \"drugs\": row['drugs'],            \n",
    "#         }\n",
    "#     )\n",
    "#     trial_docs.append(doc)\n",
    "# # trial_docs\n",
    "\n",
    "# print(trial_docs[0].metadata)\n",
    "\n",
    "# list_remove = set()\n",
    "# for i, doc in enumerate(trial_docs):\n",
    "#     if len(doc.page_content)>10000:\n",
    "#         # print(f\"trial {i} is too long\")\n",
    "#         list_remove.add(i)\n",
    "#         # print(doc.metadata)\n",
    "#     if doc.metadata['disease_category'] == 'other_conditions':\n",
    "#         # print(f\"trial {i} is other conditions\")\n",
    "#         list_remove.add(i)\n",
    "#         # print(doc.metadata)\n",
    "# # remove list_remove indexes from trial_docs\n",
    "# trial_docs = [doc for i, doc in enumerate(trial_docs) if i not in list_remove]\n",
    "# print(f\"Number of trials to be added to the vector store: {len(trial_docs)}\")\n",
    "\n",
    "# # print(len(trial_docs[11].page_content))\n",
    "# # trial_docs.pop(11)\n",
    "\n",
    "# persistent_client = chromadb.PersistentClient(path = chromadb_path)\n",
    "\n",
    "# if vstore_delete == True:\n",
    "#     vectorstore_trials.delete_collection()\n",
    "#     trials_vstore_created = False\n",
    "#     vstore_delete = False\n",
    "#     print(\"vstore deleted\")\n",
    "\n",
    "# vectorstore_trials = Chroma(\n",
    "#     client=persistent_client,\n",
    "#     collection_name=trial_collection,\n",
    "#     embedding_function=NomicEmbeddings(model=\"nomic-embed-text-v1.5\",\n",
    "#                             inference_mode='local'),\n",
    "# )\n",
    "# if vectorstore_trials._collection.count() == 0:\n",
    "#     vectorstore_trials = Chroma.from_documents(\n",
    "#         documents=trial_docs,\n",
    "#         client=persistent_client,\n",
    "#         collection_name=trial_collection,\n",
    "#         # persist_directory=chromadb_path,\n",
    "#         embedding=NomicEmbeddings(model=\"nomic-embed-text-v1.5\",\n",
    "#                                 inference_mode='local'),\n",
    "#     )\n",
    "#     trials_vstore_created = True\n",
    "#     print(\"Vectorstore is created now\")\n",
    "# else:\n",
    "#     print(\"Loading the vectorstore from persistent client\")\n",
    "\n",
    "# # collection = persistent_client.get_collection(name=trial_collection)\n",
    "# print(f\"Number of trials in the vector store: {vectorstore_trials._collection.count()}\")\n",
    "# trial_docs[0]\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Tools:\n",
    "Here we define some tools that the agent needs to use for evaluation of the patient, general policies, and clinic trials.\n",
    "Below is the list of tools:\n",
    "- Patient Data Extractor\n",
    "- Profile Maker\n",
    "- Policy Retriever\n",
    "- Policies to Questions\n",
    "- Policy Evaluator with Python Tools (multiply, date_today, date_difference, date_convert, date_split, number_compare)\n",
    "- Trials Retriever \n",
    "- Trial Grader\n",
    "- Hallucination Grader\n",
    "- Profile Rewriter"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Patient Data Extractor\n",
    "This tool extracts patient data from the sqlite database using the patient_id."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain_core.tools import tool\n",
    "from langchain_openai import ChatOpenAI\n",
    "\n",
    "from backend.helper_functions import get_patient_data\n",
    "\n",
    "# def get_patient_data(patient_id: int) -> dict:\n",
    "#     \"\"\"Fetch all fields for the patient based on the given patient_id as an integer.\n",
    "\n",
    "#     Returns:\n",
    "#         A dictionary containing the patient's medical history.        \n",
    "#     \"\"\"    \n",
    "\n",
    "#     conn = sqlite3.connect(db)\n",
    "#     cursor = conn.cursor()    \n",
    "#     query = 'SELECT * FROM patients WHERE patient_id=?'\n",
    "#     cursor.execute(query, (patient_id,))\n",
    "#     patient_data = cursor.fetchone()\n",
    "#     # rows = cursor.fetchall()\n",
    "#     column_names = [column[0] for column in cursor.description]\n",
    "#     conn.close()\n",
    "#     if patient_data is None:\n",
    "#         return None\n",
    "#     else:    \n",
    "#         results = dict(zip(column_names, patient_data))    \n",
    "#     return results\n",
    "\n",
    "# Also possible to add a new patient\n",
    "def add_patient_data(patient_data: dict):    \n",
    "    \"\"\"Adds a new patient to the SQLite database.\"\"\"\n",
    "    \n",
    "    name = patient_data['name']\n",
    "    age = patient_data['age']\n",
    "    medical_history = patient_data['medical_history']\n",
    "    previous_trials = patient_data['previous_trials']\n",
    "    trial_status = patient_data['trial_status']\n",
    "    last_trial_dates = patient_data['last_trial_dates']\n",
    "\n",
    "    conn = sqlite3.connect(db)\n",
    "    cursor = conn.cursor()\n",
    "    \n",
    "    # Insert the new patient data into the database\n",
    "    cursor.execute('''\n",
    "    INSERT INTO patients (name, age, medical_history, previous_trials, trial_status, last_trial_dates)\n",
    "    VALUES (?, ?, ?, ?, ?, ?)\n",
    "    ''', (name, age, medical_history, previous_trials, trial_status, last_trial_dates))\n",
    "    \n",
    "    conn.commit()\n",
    "    conn.close()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'patient_id': 1,\n",
       " 'name': 'Sophia Martinez',\n",
       " 'age': 72,\n",
       " 'medical_history': 'Hypertension',\n",
       " 'previous_trials': '',\n",
       " 'trial_status': '',\n",
       " 'trial_completion_date': ''}"
      ]
     },
     "execution_count": 10,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "sample_patient_id = 1\n",
    "patient_data = get_patient_data(sample_patient_id)\n",
    "patient_data"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Profile Maker\n",
    "This tool creates a a text description of the patient data as the parient profile.   \n",
    "It also suggest possible relevant medical trial categories based on the patient's disease history. "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain_core.output_parsers import StrOutputParser\n",
    "from langchain.prompts import PromptTemplate\n",
    "\n",
    "parser = StrOutputParser()\n",
    "prompt_profile = PromptTemplate(\n",
    "    template=\"\"\"\n",
    "    You are the Clinical Research Coordinator in the screening phase of a clinical trial. \n",
    "    Use the following patient data to write the patient profile for the screening phase.\n",
    "    The patient profile is a summary of the patient's information in continuous text form.    \n",
    "    If they had no previous trial participation, exclude trial status and trial completion date.\\n\n",
    "    Do not ignore any available information.\\n \n",
    "    Also suggest medical trials that can be related to patient's disease history.\\n    \n",
    "    Write the patient profile in 3 to 4 short sentences.\\n\\n\n",
    "    {patient_data}\"\"\",\n",
    "    input_variables=[\"patient_data\"],\n",
    ")\n",
    "# In a separate section of the profile, also suggest medical trial categories related to patient's disease history.\\n    \n",
    "# model = ChatOpenAI(temperature = 0.0, model=modelID)\n",
    "\n",
    "chain_profile = prompt_profile | model | parser\n",
    "# to preserve the patient's private information"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "('This is a 72-year-old patient with a history of hypertension.  The patient '\n",
      " 'has not participated in any previous clinical trials.  Given their age and '\n",
      " 'medical history, they may be eligible for trials investigating new '\n",
      " 'treatments for hypertension management or age-related cardiovascular '\n",
      " 'diseases.  \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '**Suggested Trials:**\\n'\n",
      " '\\n'\n",
      " '* **Trials focusing on new antihypertensive medications:**  These trials '\n",
      " 'often seek participants with uncontrolled hypertension.\\n'\n",
      " '* **Trials investigating lifestyle interventions for hypertension:**  These '\n",
      " 'trials may target older adults and focus on diet, exercise, or stress '\n",
      " 'management.\\n'\n",
      " '* **Trials exploring the impact of hypertension on other age-related '\n",
      " 'conditions:**  This could include trials looking at the relationship between '\n",
      " 'hypertension and cognitive decline or heart failure. \\n'\n",
      " '\\n')\n"
     ]
    }
   ],
   "source": [
    "# to preserve the patient's private information\n",
    "if patient_data.get('name'):\n",
    "    del patient_data['patient_id']\n",
    "    del patient_data['name']\n",
    "\n",
    "patient_profile = chain_profile.invoke({'patient_data': patient_data})\n",
    "nprint(patient_profile) # patient_profile"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Policy Retriever\n",
    "A retriever tool that retrieves relevant policies from policy documents based on the patient profile."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Embedding texts: 100%|██████████| 1/1 [00:00<00:00, 38.16inputs/s]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "5\n",
      "('\\n'\n",
      " '        Key Inclusion Criteria:\\r\\n'\n",
      " '\\r\\n'\n",
      " '          -  Subject must be ≥18 years of age.\\r\\n'\n",
      " '\\r\\n'\n",
      " '          -  Subjects must have documented IDH1 R132 gene-mutated advanced '\n",
      " 'hematologic malignancy\\r\\n'\n",
      " '             based on local or central evaluation.\\r\\n'\n",
      " '\\r\\n'\n",
      " '          -  Subjects must be amenable to serial bone marrow biopsies, '\n",
      " 'peripheral blood sampling,\\r\\n'\n",
      " '             and urine sampling during the study.\\r\\n'\n",
      " '\\r\\n'\n",
      " '          -  Subjects must have ECOG PS of 0 to 2.\\r\\n'\n",
      " '\\r\\n'\n",
      " '          -  Platelet count ≥20,000/µL (Transfusions to achieve this level '\n",
      " 'are allowed).\\r\\n'\n",
      " '\\r\\n'\n",
      " '          -  Subjects must have adequate hepatic function as evidenced by: '\n",
      " 'Aspartate\\r\\n'\n",
      " '             aminotransferase (AST), alanine aminotransferase (ALT), and '\n",
      " 'alkaline phosphatase (ALP)\\r\\n'\n",
      " '             ≤3.0 × ULN, unless considered due to leukemic disease and serum '\n",
      " 'total bilirubin ≤1.5 x\\r\\n'\n",
      " \"             upper limit of normal (ULN), unless considered due to Gilbert's \"\n",
      " 'disease or leukemic\\r\\n'\n",
      " '             disease\\r\\n'\n",
      " '\\r\\n'\n",
      " '          -  Subjects must have adequate renal function as evidenced by a '\n",
      " 'serum creatinine ≤2.0 ×\\r\\n'\n",
      " '             ULN or creatinine clearance >40mL/min based on Cockroft-Gault '\n",
      " 'glomerular filtration\\r\\n'\n",
      " '             rate (GFR)\\r\\n'\n",
      " '\\r\\n'\n",
      " '          -  Subjects must be recovered from any clinically relevant toxic '\n",
      " 'effects of any prior\\r\\n'\n",
      " '             surgery, radiotherapy, or other therapy intended for the '\n",
      " 'treatment of cancer.\\r\\n'\n",
      " '\\r\\n'\n",
      " '          -  Female subjects with reproductive potential must have a '\n",
      " 'negative serum pregnancy test\\r\\n'\n",
      " '             within 7 days prior to the start of therapy and on the first '\n",
      " 'day of study drug\\r\\n'\n",
      " '             administration.\\r\\n'\n",
      " '\\r\\n'\n",
      " '        Key Exclusion Criteria:\\r\\n'\n",
      " '\\r\\n'\n",
      " '          -  Subjects who have undergone hematopoietic stem cell transplant '\n",
      " '(HSCT) within 60 days\\r\\n'\n",
      " '             of the first dose of AG-120, or subjects on immunosuppressive '\n",
      " 'therapy post HSCT at the\\r\\n'\n",
      " '             time of screening, or with clinically significant '\n",
      " 'graft-versus-host disease (GVHD).\\r\\n'\n",
      " '             (The use of a stable dose of oral steroids post HSCT and/or '\n",
      " 'topical for ongoing skin\\r\\n'\n",
      " '             GVHD is permitted.)\\r\\n'\n",
      " '\\r\\n'\n",
      " '          -  Subjects who received systemic anticancer therapy or '\n",
      " 'radiotherapy <14 days prior to\\r\\n'\n",
      " '             their first day of study drug administration. (Hydroxyurea is '\n",
      " 'allowed prior to\\r\\n'\n",
      " '             enrollment and after the start of AG-120).\\r\\n'\n",
      " '\\r\\n'\n",
      " '          -  Subjects who received an investigational agent <14 days prior '\n",
      " 'to their first day of\\r\\n'\n",
      " '             study drug administration.\\r\\n'\n",
      " '\\r\\n'\n",
      " '          -  Subjects who are pregnant or breastfeeding.\\r\\n'\n",
      " '\\r\\n'\n",
      " '          -  Subjects with an active severe infection or with an unexplained '\n",
      " 'fever >38.5°C during\\r\\n'\n",
      " '             screening visits or on their first day of study drug '\n",
      " 'administration (at the discretion\\r\\n'\n",
      " '             of the Investigator, subjects with tumor fever may be '\n",
      " 'enrolled).\\r\\n'\n",
      " '\\r\\n'\n",
      " '          -  Subjects with New York Heart Association (NYHA) Class III or IV '\n",
      " 'congestive heart\\r\\n'\n",
      " '             failure or LVEF <40% by echocardiogram (ECHO) or multi-gated '\n",
      " 'acquisition (MUGA) scan\\r\\n'\n",
      " '             within approximately 28 days of C1D1.\\r\\n'\n",
      " '\\r\\n'\n",
      " '          -  Subjects with a history of myocardial infarction within the '\n",
      " 'last 6 months of\\r\\n'\n",
      " '             screening.\\r\\n'\n",
      " '\\r\\n'\n",
      " '          -  Subjects with a known unstable or uncontrolled angina '\n",
      " 'pectoris.\\r\\n'\n",
      " '\\r\\n'\n",
      " '          -  Subjects with a known history of severe and/or uncontrolled '\n",
      " 'ventricular arrhythmias.\\r\\n'\n",
      " '\\r\\n'\n",
      " '          -  Subjects with known unstable or uncontrolled angina '\n",
      " 'pectoris.\\r\\n'\n",
      " '\\r\\n'\n",
      " '          -  Subjects with heart-rate corrected QT (QTc) interval ≥450 ms or '\n",
      " 'other factors that\\r\\n'\n",
      " '             increase the risk of QT prolongation or arrhythmic events.\\r\\n'\n",
      " '\\r\\n'\n",
      " '          -  Patients taking medications that are known to prolong the QT '\n",
      " 'interval\\r\\n'\n",
      " '\\r\\n'\n",
      " '          -  Subjects with known infection with human immunodeficiency virus '\n",
      " '(HIV) or active\\r\\n'\n",
      " '             hepatitis B or C.\\r\\n'\n",
      " '\\r\\n'\n",
      " '          -  Subjects with clinical symptoms suggesting active central '\n",
      " 'nervous system (CNS)\\r\\n'\n",
      " '             leukemia or known CNS leukemia. Evaluation of cerebrospinal '\n",
      " 'fluid is only required if\\r\\n'\n",
      " '             there is a clinical suspicion of CNS involvement by leukemia '\n",
      " 'during screening.\\r\\n'\n",
      " '\\r\\n'\n",
      " '          -  Subjects with immediately life-threatening, severe '\n",
      " 'complications of leukemia such as\\r\\n'\n",
      " '             uncontrolled bleeding, pneumonia with hypoxia or shock, and/or '\n",
      " 'disseminated\\r\\n'\n",
      " '             intravascular coagulation.\\r\\n'\n",
      " '      ')\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "[Document(metadata={'drugs': \"['ag-120']\", 'diseases': \"['relapsed or refractory acute myeloid leukemia (aml)', 'untreated aml', 'other idh1-mutated positive hematologic malignancies', 'myelodysplastic syndromes']\", 'disease_category': 'leukemia', 'status': 'recruiting', 'nctid': 'NCT02074839'}, page_content=\"\\n        Key Inclusion Criteria:\\r\\n\\r\\n          -  Subject must be ≥18 years of age.\\r\\n\\r\\n          -  Subjects must have documented IDH1 R132 gene-mutated advanced hematologic malignancy\\r\\n             based on local or central evaluation.\\r\\n\\r\\n          -  Subjects must be amenable to serial bone marrow biopsies, peripheral blood sampling,\\r\\n             and urine sampling during the study.\\r\\n\\r\\n          -  Subjects must have ECOG PS of 0 to 2.\\r\\n\\r\\n          -  Platelet count ≥20,000/µL (Transfusions to achieve this level are allowed).\\r\\n\\r\\n          -  Subjects must have adequate hepatic function as evidenced by: Aspartate\\r\\n             aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP)\\r\\n             ≤3.0 × ULN, unless considered due to leukemic disease and serum total bilirubin ≤1.5 x\\r\\n             upper limit of normal (ULN), unless considered due to Gilbert's disease or leukemic\\r\\n             disease\\r\\n\\r\\n          -  Subjects must have adequate renal function as evidenced by a serum creatinine ≤2.0 ×\\r\\n             ULN or creatinine clearance >40mL/min based on Cockroft-Gault glomerular filtration\\r\\n             rate (GFR)\\r\\n\\r\\n          -  Subjects must be recovered from any clinically relevant toxic effects of any prior\\r\\n             surgery, radiotherapy, or other therapy intended for the treatment of cancer.\\r\\n\\r\\n          -  Female subjects with reproductive potential must have a negative serum pregnancy test\\r\\n             within 7 days prior to the start of therapy and on the first day of study drug\\r\\n             administration.\\r\\n\\r\\n        Key Exclusion Criteria:\\r\\n\\r\\n          -  Subjects who have undergone hematopoietic stem cell transplant (HSCT) within 60 days\\r\\n             of the first dose of AG-120, or subjects on immunosuppressive therapy post HSCT at the\\r\\n             time of screening, or with clinically significant graft-versus-host disease (GVHD).\\r\\n             (The use of a stable dose of oral steroids post HSCT and/or topical for ongoing skin\\r\\n             GVHD is permitted.)\\r\\n\\r\\n          -  Subjects who received systemic anticancer therapy or radiotherapy <14 days prior to\\r\\n             their first day of study drug administration. (Hydroxyurea is allowed prior to\\r\\n             enrollment and after the start of AG-120).\\r\\n\\r\\n          -  Subjects who received an investigational agent <14 days prior to their first day of\\r\\n             study drug administration.\\r\\n\\r\\n          -  Subjects who are pregnant or breastfeeding.\\r\\n\\r\\n          -  Subjects with an active severe infection or with an unexplained fever >38.5°C during\\r\\n             screening visits or on their first day of study drug administration (at the discretion\\r\\n             of the Investigator, subjects with tumor fever may be enrolled).\\r\\n\\r\\n          -  Subjects with New York Heart Association (NYHA) Class III or IV congestive heart\\r\\n             failure or LVEF <40% by echocardiogram (ECHO) or multi-gated acquisition (MUGA) scan\\r\\n             within approximately 28 days of C1D1.\\r\\n\\r\\n          -  Subjects with a history of myocardial infarction within the last 6 months of\\r\\n             screening.\\r\\n\\r\\n          -  Subjects with a known unstable or uncontrolled angina pectoris.\\r\\n\\r\\n          -  Subjects with a known history of severe and/or uncontrolled ventricular arrhythmias.\\r\\n\\r\\n          -  Subjects with known unstable or uncontrolled angina pectoris.\\r\\n\\r\\n          -  Subjects with heart-rate corrected QT (QTc) interval ≥450 ms or other factors that\\r\\n             increase the risk of QT prolongation or arrhythmic events.\\r\\n\\r\\n          -  Patients taking medications that are known to prolong the QT interval\\r\\n\\r\\n          -  Subjects with known infection with human immunodeficiency virus (HIV) or active\\r\\n             hepatitis B or C.\\r\\n\\r\\n          -  Subjects with clinical symptoms suggesting active central nervous system (CNS)\\r\\n             leukemia or known CNS leukemia. Evaluation of cerebrospinal fluid is only required if\\r\\n             there is a clinical suspicion of CNS involvement by leukemia during screening.\\r\\n\\r\\n          -  Subjects with immediately life-threatening, severe complications of leukemia such as\\r\\n             uncontrolled bleeding, pneumonia with hypoxia or shock, and/or disseminated\\r\\n             intravascular coagulation.\\r\\n      \"),\n",
       " Document(metadata={'disease_category': 'leukemia', 'diseases': \"['myelodysplastic syndromes', 'chronic myelomonocytic leukemia', 'acute myeloid leukemia']\", 'status': 'recruiting', 'drugs': \"['astx727', 'dacogen']\", 'nctid': 'NCT03306264'}, page_content=\"\\n        Inclusion Criteria:\\r\\n\\r\\n          1. Able to understand and comply with the study procedures, understand the risks involved\\r\\n             in the study, and provide written informed consent before the first study-specific\\r\\n             procedure; specifically able to comply with the PK assessment schedule during the\\r\\n             first 2 treatment cycles.\\r\\n\\r\\n          2. Men or women ≥18 years who are candidates to receive IV decitabine according to FDA or\\r\\n             European Medicines Agency (EMA) approved indications:\\r\\n\\r\\n               1. In North America: Participants with MDS previously treated or untreated with de\\r\\n                  novo or secondary MDS, including all French-American-British subtypes (refractory\\r\\n                  anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess\\r\\n                  blasts, refractory anemia with excess blasts in transformation, and chronic\\r\\n                  myelomonocytic leukemia [CMML]), and subjects with MDS International Prognostic\\r\\n                  Scoring System (IPSS) int-1, -2, or high-risk MDS.\\r\\n\\r\\n               2. In Europe: Participants with de novo or secondary AML, as defined by the World\\r\\n                  Health Organization (WHO) criteria, who are not candidates for standard induction\\r\\n                  chemotherapy.\\r\\n\\r\\n          3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.\\r\\n\\r\\n          4. Adequate organ function defined as follows:\\r\\n\\r\\n               1. Hepatic: Total or direct bilirubin ≤2 × upper limit of normal (ULN); aspartate\\r\\n                  transaminase/serum glutamic oxaloacetic transaminase (AST/SGOT) and alanine\\r\\n                  transaminase/serum glutamic pyruvic transaminase (ALT/SGPT) ≤2.5 × ULN.\\r\\n\\r\\n               2. Renal: serum creatinine ≤1.5 × ULN or calculated creatinine clearance or\\r\\n                  glomerular filtration rate >50 mL/min/1.73 m2 for subjects with creatinine levels\\r\\n                  above institutional normal.\\r\\n\\r\\n          5. No major surgery within 30 days of first study treatment.\\r\\n\\r\\n          6. Life expectancy of at least 3 months.\\r\\n\\r\\n          7. Women of child-bearing potential must not be pregnant or breastfeeding and must have a\\r\\n             negative pregnancy test at screening. Women of non-childbearing potential are those\\r\\n             who have had a hysterectomy or bilateral oophorectomy, or who have completed\\r\\n             menopause, defined as no menses for at least 1 year AND either age ≥65 years or\\r\\n             follicle-stimulating hormone levels in the menopausal range.\\r\\n\\r\\n          8. Subjects and their partners with reproductive potential must agree to use effective\\r\\n             contraceptive measures during the study and for 3 months after the last dose of study\\r\\n             treatment. Effective contraception includes methods such as oral contraceptives or\\r\\n             double-barrier method (eg, use of a condom AND diaphragm, with spermicide).\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          1. Prior treatment with more than 1 cycle of azacitidine or decitabine. Prior cytotoxic\\r\\n             chemotherapy for AML except for hydroxyurea to control high white blood cell (WBC)\\r\\n             counts.\\r\\n\\r\\n          2. Hospitalization for more than 2 days for documented febrile neutropenia, pneumonia,\\r\\n             sepsis, or systemic infection in the 30 days before screening.\\r\\n\\r\\n          3. Treatment with any investigational drug or therapy within 2 weeks of study treatment,\\r\\n             or 5 half-lives, whichever is longer, before the first dose of study treatment, or\\r\\n             ongoing clinically significant adverse events (AEs) from previous treatment.\\r\\n\\r\\n          4. Cytotoxic chemotherapy or prior azacitidine or decitabine within 4 weeks of first dose\\r\\n             of study treatment.\\r\\n\\r\\n          5. Concurrent MDS therapies, including lenalidomide, erythropoietin,\\r\\n             cyclosporine/tacrolimus, granulocyte-colony stimulating factor (G-CSF),\\r\\n             granulocyte-macrophage colony-stimulating factor, etc. (Prior treatment with these\\r\\n             agents is permitted, provided that completion is at least 1 week before the first dose\\r\\n             of study treatment.)\\r\\n\\r\\n          6. Poor medical risk because of other conditions such as uncontrolled systemic diseases,\\r\\n             active uncontrolled infections, or comorbidities that may put the patient at risk of\\r\\n             not being able to complete at least 2 cycles of treatment.\\r\\n\\r\\n          7. Known significant mental illness or other condition, such as active alcohol or other\\r\\n             substance abuse or addiction, that in the opinion of the investigator predisposes the\\r\\n             subject to high risk of noncompliance with the protocol.\\r\\n\\r\\n          8. Rapidly progressive or highly proliferative disease (total white blood cell count of\\r\\n             >15 × 10^9/L) or other criteria that render the subject at high risk of requiring\\r\\n             intensive cytotoxic chemotherapy within the next 3 months.\\r\\n\\r\\n          9. Life-threatening illness or severe organ system dysfunction, such as uncontrolled\\r\\n             congestive heart failure or chronic obstructive pulmonary disease, or other reasons\\r\\n             including laboratory abnormalities, which, in the investigator's opinion, could\\r\\n             compromise the subject's safety, interfere with the absorption or metabolism of\\r\\n             ASTX727, or compromise completion of the study or integrity of the study outcomes.\\r\\n\\r\\n         10. Prior malignancy, except for adequately treated basal cell or squamous cell skin\\r\\n             cancer, in situ cervical cancer, prostate cancer or breast cancer under control with\\r\\n             hormone therapy, or other cancer from which the subject has been disease free for at\\r\\n             least 2 years.\\r\\n      \"),\n",
       " Document(metadata={'nctid': 'NCT02588781', 'diseases': \"['colorectal cancer']\", 'disease_category': 'cancer', 'status': 'recruiting', 'drugs': \"['pemetrexed']\"}, page_content='\\n        Inclusion Criteria:\\r\\n\\r\\n          1. Subject is at least 20 years of age.\\r\\n\\r\\n          2. Written and voluntary informed consent understood, signed and dated.\\r\\n\\r\\n          3. They must have refractory or progressive colorectal cancer for which there is no\\r\\n             further curative therapy available.\\r\\n\\r\\n          4. Subject able to adhere to the study visit schedule and other protocol requirements.\\r\\n\\r\\n          5. ECOG 0-2\\r\\n\\r\\n          6. At least one measurable lesion that can be accurately assessed by imaging or physical\\r\\n             examination at baseline and following up visits.\\r\\n\\r\\n          7. Must have a life expectancy of 3 months or more\\r\\n\\r\\n          8. Demonstrate adequate organ function\\r\\n\\r\\n          9. Negative urine or serum pregnancy test within 28 days of study treatment\\r\\n\\r\\n         10. Be willing to provide fresh tissue for biomarker analysis, and, based on the adequacy\\r\\n             of the tissue sample quality for assessment of biomarker status.\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          1. ECOG ≥ 3\\r\\n\\r\\n          2. History of malignancy in the last 5 years.\\r\\n\\r\\n          3. Subject has known historical or active infection with HIV, hepatitis B, or hepatitis\\r\\n             C.\\r\\n\\r\\n          4. Breast-feeding or pregnant female\\r\\n\\r\\n          5. Patients can not the administration of Folic acid or Vitamin B12.\\r\\n\\r\\n          6. Before treatment with Pemetrexed.\\r\\n\\r\\n          7. Patients who can not swallow oral medication.\\r\\n\\r\\n          8. The most recent treatment with the clinical trial for the drug for 14 days prior to\\r\\n             enrollment.\\r\\n\\r\\n          9. Systemic chemotherapy within three weeks after the administration of the last before\\r\\n             the test treatment, radiation therapy patients who had been administered.\\r\\n\\r\\n         10. Except for the hair loss, it is induced before cancer treatment, all of toxicity in\\r\\n             progress (> CTCAE1 grade).\\r\\n\\r\\n         11. Upper GI bleeding within registration before 4 weeks of Bowel obstruction or CTCAE3 or\\r\\n             4 grade.\\r\\n\\r\\n         12. Subject who experienced a recent myocardial infarction, including severe/unstable\\r\\n             angina pectoris, coronary/peripheral artery bypass graft, uncontrolled hypertension,\\r\\n             clinically significant cardiac dysrhythmia or clinically significant electrocardiogram\\r\\n             (ECG) abnormality, significant or uncontrolled cardiovascular disease CHF, and\\r\\n             cerebrovascular accident or transient ischemic attack, or seizure disorder in the past\\r\\n             year.\\r\\n      '),\n",
       " Document(metadata={'disease_category': 'cancer', 'status': 'recruiting', 'drugs': \"['abiraterone', 'apitolisib', 'ipatasertib', 'placebo', 'prednisone', 'prednisolone']\", 'nctid': 'NCT01485861', 'diseases': \"['prostate cancer']\"}, page_content='\\n        Inclusion Criteria:\\r\\n\\r\\n          -  Histologically confirmed metastatic or advanced prostate adenocarcinoma that has been\\r\\n             previously treated with docetaxel-based therapy and has progressed during treatment of\\r\\n             at least one hormonal therapy(prior docetaxel is not required for the safety cohort)\\r\\n\\r\\n          -  Two rising PSA levels greater than or equal to (>/=) 2 ng/mL measured >/= 1 week apart\\r\\n             or radiographic evidence of disease progression in soft tissue or bone\\r\\n\\r\\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at screening\\r\\n\\r\\n          -  Adequate hematologic and organ function\\r\\n\\r\\n          -  Documented willingness to use an effective means of contraception\\r\\n\\r\\n          -  Safety cohort only: agreement to use CGM for first cycle of treatment\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          -  History of Type I or Type II diabetes mellitus requiring insulin; safety cohort:\\r\\n             patients who are receiving any pharmacologic treatment for diabetes are not eligible\\r\\n\\r\\n          -  New York Heart Association Class III or IV heart failure or Left ventricular ejection\\r\\n             fraction < 50% or ventricular arrhythmia requiring medication\\r\\n\\r\\n          -  Significant atherosclerotic disease, as evidenced by: unstable angina, history of\\r\\n             myocardial infarction within 6 months prior to Day 1, or cerebrovascular accident\\r\\n             within 6 months prior to Day 1\\r\\n\\r\\n          -  Active autoimmune disease that is not controlled by nonsteroidal anti-inflammatory\\r\\n             drugs or active inflammatory disease which requires immunosuppressive therapy\\r\\n\\r\\n          -  Clinically significant history of liver disease\\r\\n\\r\\n          -  History of adrenal insufficiency or hyperaldosteronism\\r\\n\\r\\n          -  Phase II only: Previous therapy for prostate cancer with 17\\r\\n             alpha-hydroxylase/C17,20-lyase inhibitors, including abiraterone\\r\\n\\r\\n          -  Phase II only: Previous treatment for prostate cancer with Protein kinase B\\r\\n             phosphatidylinositol 3 kinase and/or mammalian target of rapamycin inhibitors\\r\\n\\r\\n          -  Need for chronic corticosteroid therapy of >/= 20 mg of prednisone per day or an\\r\\n             equivalent dose of other anti inflammatory corticosteroids or immunosuppressant\\r\\n      '),\n",
       " Document(metadata={'disease_category': 'leukemia', 'status': 'recruiting', 'drugs': \"['etoposide', 'cyclophosphamide']\", 'nctid': 'NCT02094794', 'diseases': \"['adult acute myeloid leukemia with 11q23 (mll) abnormalities', 'adult acute myeloid leukemia with del(5q)', 'adult acute myeloid leukemia with inv(16)(p13;q22)', 'adult acute myeloid leukemia with t(15;17)(q22;q12)', 'adult acute myeloid leukemia with t(16;16)(p13;q22)', 'adult acute myeloid leukemia with t(8;21)(q22;q22)', 'recurrent adult acute lymphoblastic leukemia', 'recurrent adult acute myeloid leukemia', 'recurrent childhood acute lymphoblastic leukemia', 'recurrent childhood acute myeloid leukemia']\"}, page_content='\\n        Inclusion Criteria:\\r\\n\\r\\n          -  Participant has the ability and the willingness to sign the informed consent document\\r\\n             (for adults only, for participants with mild cognitive abilities may use a legally\\r\\n             authorized representative)\\r\\n\\r\\n          -  Documented (signed) informed consent; the patient, family member and transplant staff\\r\\n             physician (physician, nurse, and social worker) meet at least once prior to starting\\r\\n             the transplant procedure; during this meeting all pertinent information with respect\\r\\n             to risks and benefits to donor and recipient will be presented; alternative treatment\\r\\n             modalities will be discussed; the risks are explained in detail in the enclosed\\r\\n             consent forms\\r\\n\\r\\n          -  Karnofsky performance status >= 70% =< 2\\r\\n\\r\\n          -  Acute lymphocytic leukemia or acute myelogenous leukemia who are not in first\\r\\n             remission or second remission i.e. after failing induction therapy, or in relapse or\\r\\n             beyond second remission; (prior therapy with VP-16 and Cytoxan is allowed)\\r\\n\\r\\n          -  All candidates for this study must have a human leukocyte antigen (HLA) (A, B, C, DR)\\r\\n             identical siblings who is willing to donate bone marrow or primed blood stem cells or\\r\\n             a 10/10 allele matched unrelated donor; a single allele mismatch at A, B, C, DR or DQ\\r\\n             and a killer immunoglobulin-like receptor (KIR) mismatch at C will be allowed; all ABO\\r\\n             blood group combinations of the donor/recipient are acceptable\\r\\n\\r\\n          -  The time from the end last induction, re-induction, or consolidation regimen should be\\r\\n             greater than or equal to 14 days from planned start of study treatment; Note:\\r\\n             Chemotherapy given within 14 days of planned study enrollment for the purpose of\\r\\n             controlling counts is permitted\\r\\n\\r\\n          -  Total bilirubin =< 1.5 x upper limit of normal (ULN) OR 3 x ULN for Gilbert\\'s disease\\r\\n\\r\\n          -  Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamate pyruvate\\r\\n             transaminase (SGPT) =< 5 x ULN\\r\\n\\r\\n          -  Measured creatinine clearance >= 80 ml/min per 24 hour urine collection OR serum\\r\\n             creatinine =< 1.3 mg/dL\\r\\n\\r\\n          -  Women of child bearing potential only: Negative urine or serum pregnancy test\\r\\n\\r\\n          -  Pulmonary function tests: Forced expiratory volume in one second (FEV1) and carbon\\r\\n             monoxide diffusion capacity (DLCO) (adjusted for Hb) >= 50% adjusted of predicted\\r\\n             normal value\\r\\n\\r\\n          -  Echocardiogram (ECHO) or multi gated acquisition scan (MUGA): ejection fraction of >=\\r\\n             50% AND no finding of abnormal wall motion (i.e. report does not indicate that wall\\r\\n             motion is \"abnormal\" or \"altered\")\\r\\n\\r\\n          -  Electrocardiogram (EKG) showing no ischemic changes and no abnormal rhythm\\r\\n\\r\\n          -  Agreement of men AND women-of-child-bearing-potential to use adequate contraception\\r\\n             (hormonal or barrier method of birth control or abstinence) prior to study entry and\\r\\n             for six months following duration of study participation; should a woman become\\r\\n             pregnant or suspect that she is pregnant while participating on the trial, she should\\r\\n             inform her treating physician immediately\\r\\n\\r\\n          -  DONOR ELIGIBILITY: Donor evaluation and eligibility will be assessed as per current\\r\\n             City of Hope standard operating procedure (SOP)\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          -  Prior autologous or allogeneic hematopoietic stem cell\\r\\n\\r\\n          -  Prior radiation therapy that would exclude the use of TMLI\\r\\n\\r\\n          -  Plans during the trial to receive any other (non-trial) investigational agents, or\\r\\n             concurrent biological, chemotherapy, or radiation therapy; (chemotherapy for white\\r\\n             blood count control is permitted)\\r\\n\\r\\n          -  Uncontrolled illness including ongoing or active infection\\r\\n\\r\\n          -  History of allergic reactions attributed to compounds of similar chemical or biologic\\r\\n             composition to etoposide\\r\\n\\r\\n          -  Patients with other active malignancies are ineligible for this study, other than\\r\\n             localized malignancies\\r\\n\\r\\n          -  Patients with psychological or medical condition that patient\\'s physician deems\\r\\n             unacceptable to proceed to allogeneic hematopoietic stem cell transplantation\\r\\n\\r\\n          -  Women who are planning to become pregnant or breast feed during the trial\\r\\n\\r\\n          -  Subjects, who in the opinion of the investigator, may not be able to comply with the\\r\\n             safety monitoring requirements of the study\\r\\n      ')]"
      ]
     },
     "execution_count": 13,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "retriever_policy = vectorstore.as_retriever(search_kwargs={\"k\": n_retrieved_policies})\n",
    "\n",
    "# sample policy retrieval\n",
    "docs_retrieved = retriever_policy.get_relevant_documents(patient_profile)\n",
    "print(len(docs_retrieved))\n",
    "doc_txt = docs_retrieved[0].page_content\n",
    "nprint(doc_txt)\n",
    "docs_retrieved"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Policies to Questions\n",
    "Each main policy document also consists of a list of sub-policies related to the same category. For example, a policy may contain eligible and non-eligible sub-policies for a give patient. This is a challenging condition for an llm to determine the patient's eligibility in a single shot attempt.   \n",
    "To assist the llm and prevent possible mistakes, we convert each subpolicy to a direct yes/no question with a yes answer indicating the patient is not eligible.   \n",
    "We define an llm chain for that purpose."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Policies --> questions\n",
    "from langchain_core.pydantic_v1 import BaseModel, Field\n",
    "\n",
    "prompt_rps = PromptTemplate(\n",
    "    template=\"\"\" You are a Principal Investigator (PI) for clinical trials. \n",
    "        The following document contains a policy document about participation in clinial trials:\n",
    "        \\n\\n{policy}\\n\\b\n",
    "\n",
    "        Your task is to rephrase each single policy from the document above into a single yes/no question. \n",
    "        Form each question so that a yes answer indicates the patient's ineligibility.\n",
    "        Do not create more questions than given number of policies.\n",
    "\n",
    "        Example: Patients who have had accidents in the past 10 months are not eligible\n",
    "        rephrased: Did patient have an accident in the past 10 months?\n",
    "\n",
    "        Example: Patients with active tuberculosis, hepatitis B or C, or HIV are excluded unless the trial is specifically designed for these conditions.\n",
    "        rephrased: Did patient have active tuberculosis, hepatitis B or C, or HIV?\n",
    "        \"\"\",\n",
    "    input_variables=[\"policy\"],\n",
    ")\n",
    "\n",
    "class policy_relevance(BaseModel):\n",
    "    \"policy relevance score\"\n",
    "\n",
    "    relevant: str = Field(description=\"is policy relevant? 'yes' or 'no'.\")\n",
    "    reason: str\n",
    "\n",
    "parser = StrOutputParser()\n",
    "\n",
    "policy_rps_chain = prompt_rps | model | parser\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "('Here are the inclusion/exclusion criteria rephrased as yes/no questions, '\n",
      " 'where \"yes\" indicates ineligibility:\\n'\n",
      " '\\n'\n",
      " '**Inclusion Criteria:**\\n'\n",
      " '\\n'\n",
      " '* **Age:** Is the patient younger than 18 years old? \\n'\n",
      " '* **Disease:** Does the patient NOT have documented IDH1 R132 gene-mutated '\n",
      " 'advanced hematologic malignancy?\\n'\n",
      " '* **Sampling:** Is the patient unable to undergo serial bone marrow '\n",
      " 'biopsies, peripheral blood sampling, and urine sampling?\\n'\n",
      " '* **Performance Status:** Does the patient have an ECOG PS of 3 or greater?\\n'\n",
      " \"* **Platelets:** Is the patient's platelet count below 20,000/µL (and \"\n",
      " 'unwilling to receive transfusions to achieve this level)?\\n'\n",
      " '* **Liver Function:**  Does the patient have AST, ALT, or ALP greater than '\n",
      " '3.0 × ULN (not considered due to leukemic disease) OR total bilirubin '\n",
      " \"greater than 1.5 × ULN (not considered due to Gilbert's disease or leukemic \"\n",
      " 'disease)?\\n'\n",
      " \"* **Kidney Function:** Is the patient's serum creatinine greater than 2.0 × \"\n",
      " 'ULN OR creatinine clearance less than 40mL/min based on Cockroft-Gault GFR?\\n'\n",
      " '* **Prior Treatment Recovery:** Does the patient have ongoing clinically '\n",
      " 'relevant toxic effects from prior surgery, radiotherapy, or other cancer '\n",
      " 'therapy?\\n'\n",
      " '* **Pregnancy:** Is the female patient with reproductive potential NOT able '\n",
      " 'to provide a negative serum pregnancy test within 7 days prior to the start '\n",
      " 'of therapy and on the first day of study drug administration?\\n'\n",
      " '\\n'\n",
      " '**Exclusion Criteria:**\\n'\n",
      " '\\n'\n",
      " '* **Hematopoietic Stem Cell Transplant:** Did the patient undergo HSCT '\n",
      " 'within 60 days of the first dose of AG-120, are they on immunosuppressive '\n",
      " 'therapy post HSCT, or have clinically significant GVHD?\\n'\n",
      " '* **Recent Systemic Therapy:** Did the patient receive systemic anticancer '\n",
      " 'therapy or radiotherapy less than 14 days prior to their first day of study '\n",
      " 'drug administration? (Hydroxyurea is allowed prior to enrollment and after '\n",
      " 'the start of AG-120).\\n'\n",
      " '* **Recent Investigational Agent:** Did the patient receive an '\n",
      " 'investigational agent less than 14 days prior to their first day of study '\n",
      " 'drug administration?\\n'\n",
      " '* **Pregnancy/Breastfeeding:** Is the patient pregnant or breastfeeding?\\n'\n",
      " '* **Active Infection:** Does the patient have an active severe infection or '\n",
      " 'unexplained fever >38.5°C during screening visits or on their first day of '\n",
      " 'study drug administration? (At the discretion of the Investigator, subjects '\n",
      " 'with tumor fever may be enrolled).\\n'\n",
      " '* **Heart Failure:** Does the patient have NYHA Class III or IV congestive '\n",
      " 'heart failure or LVEF <40% by echocardiogram (ECHO) or multi-gated '\n",
      " 'acquisition (MUGA) scan within approximately 28 days of C1D1?\\n'\n",
      " '* **Recent Myocardial Infarction:** Did the patient have a history of '\n",
      " 'myocardial infarction within the last 6 months of screening?\\n'\n",
      " '* **Unstable Angina:** Does the patient have a known history of severe '\n",
      " 'and/or uncontrolled angina pectoris?\\n'\n",
      " '* **Ventricular Arrhythmias:** Does the patient have a known history of '\n",
      " 'severe and/or uncontrolled ventricular arrhythmias?\\n'\n",
      " '* **QT Interval:** Does the patient have a heart-rate corrected QT (QTc) '\n",
      " 'interval ≥450 ms or other factors that increase the risk of QT prolongation '\n",
      " 'or arrhythmic events?\\n'\n",
      " '* **QT Prolonging Medications:** Is the patient taking medications that are '\n",
      " 'known to prolong the QT interval?\\n'\n",
      " '* **HIV/Hepatitis:** Does the patient have known infection with HIV or '\n",
      " 'active hepatitis B or C?\\n'\n",
      " '* **CNS Leukemia:** Does the patient have clinical symptoms suggesting '\n",
      " 'active central nervous system (CNS) leukemia or known CNS leukemia?\\n'\n",
      " '* **Life-Threatening Complications:** Does the patient have immediately '\n",
      " 'life-threatening, severe complications of leukemia such as uncontrolled '\n",
      " 'bleeding, pneumonia with hypoxia or shock, and/or disseminated intravascular '\n",
      " 'coagulation? \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n')\n"
     ]
    }
   ],
   "source": [
    "\n",
    "policy = docs_retrieved[0].page_content\n",
    "policy_qs = policy_rps_chain.invoke({\"policy\": policy})\n",
    "nprint(policy_qs)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Policy Evaluator with Python Tools\n",
    "\n",
    "The policy evaluator uses Python tools to evaluate the patient's eligibility.\n",
    "More often the patient's profiles or the policy documents contain date or numeric information. However, llms are not able to process these types of information properly. Therefore, we use Python tools for the model to perform numerical or date calculations and convertions.\n",
    "\n",
    "Note: You can also try the python REPL tool to give LLM more flexibility and freedon to do all kinds of calculations. However, this tool needs fine-tuned guardrails and also clear instructions on how to use it. Otherwise llm may use it even for non-numerical simulations."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain_core.tools import StructuredTool\n",
    "from datetime import date, datetime\n",
    "from langchain_core.prompts import ChatPromptTemplate\n",
    "from langgraph.prebuilt import create_react_agent\n",
    "\n",
    "\n",
    "def policy_tools(policy_qs: str, patient_profile: str, model_agent):\n",
    "    class CalculatorInput(BaseModel):\n",
    "        num1: float = Field(description=\"first number\")\n",
    "        num2: float = Field(description=\"second number\")\n",
    "\n",
    "    def multiply(num1: float, num2: float) -> float:\n",
    "        \"multiplies two input numbers together, num1 and num2\"\n",
    "        return (num1 * num2)\n",
    "\n",
    "    multiply_tool = StructuredTool.from_function(\n",
    "        func=multiply,\n",
    "        name=\"multiply\",\n",
    "        description=\"multiply numbers\",\n",
    "        args_schema=CalculatorInput,\n",
    "        # return_direct=True,    \n",
    "    )\n",
    "\n",
    "    @tool(\"date_today-tool\")\n",
    "    def date_today() -> datetime.date:\n",
    "        \"returns today date\"\n",
    "        return datetime.today().date()    \n",
    "\n",
    "    def date_difference(date1: date, date2: date) -> int:\n",
    "        \"The number of months date1 is before date2\"\n",
    "        # \"How many months before date2 is date1?\"\n",
    "        month_difference = (date2.year - date1.year) * 12 + date2.month - date1.month\n",
    "        return f'{month_difference} months'\n",
    "\n",
    "    class dates(BaseModel):\n",
    "        date1: date = Field(description=\"first date\")\n",
    "        date2: date = Field(description=\"second date\")\n",
    "\n",
    "    date_difference_tool = StructuredTool.from_function(\n",
    "        func=date_difference,\n",
    "        name=\"date_difference\",\n",
    "        description=\"The number of months first date is before second date\",\n",
    "        args_schema=dates,\n",
    "        # return_direct=True,    \n",
    "    )\n",
    "\n",
    "    class date_class(BaseModel):\n",
    "        date: str = Field(description=\"A date string in the format YYYY-MM-DD\")    \n",
    "\n",
    "    @tool(\"date_convert-tool\", args_schema=date_class)\n",
    "    def date_convert(date: str) -> date:\n",
    "        \"Converts a date string to a date object\"\n",
    "        # \"How many months before date2 is date1?\"\n",
    "        date = datetime.strptime(date, \"%Y-%m-%d\").date()\n",
    "        return date\n",
    "\n",
    "    @tool(\"date_split-tool\", args_schema=date_class)\n",
    "    def date_split(date: str) -> date:\n",
    "        \"Extracts the year and month from a date string\"\n",
    "        # \"How many months before date2 is date1?\"\n",
    "        date = datetime.strptime(date, \"%Y-%m-%d\").date()\n",
    "        year = date.year\n",
    "        month = date.month\n",
    "        return f'year: {year}, month: {month}'\n",
    "\n",
    "    @tool(\"number_comparison-tool\", args_schema=CalculatorInput)\n",
    "    def number_compare(num1: float, num2: float) -> bool:\n",
    "        \"Determines if first number is less than the second number\"\n",
    "        # \"How many months before date2 is date1?\"\n",
    "        num1_less_num1 = num1 < num2\n",
    "        return num1_less_num1\n",
    "\n",
    "    tools = [multiply_tool, date_today, date_difference_tool, date_split, number_compare]\n",
    "\n",
    "    tool_names=\", \".join([tool.name for tool in tools])\n",
    "\n",
    "    system_message = f\"\"\"\n",
    "    You are a Principal Investigator (PI) for evaluating patients for clinical trials.\n",
    "    You are asked to compare the patient profile document to the institution policy questions.\n",
    "    You must determine if the patient is eligible based on the following documnents.\n",
    "\n",
    "    \\n #### Here is the patient profile document: \\n {patient_profile}\\n\\n\n",
    "\n",
    "    If the answer to any policy question is yes, then the patient is not eligible.\\n\n",
    "    If the answer to the question is not provided in the patient profile, answer 'no'.\\n\n",
    "\n",
    "    Give a binary 'yes' or 'no' score in the response to indicate whether the patient is eligible according to the given policy ONLY.\n",
    "    If the patient is not eligible then also include the reason in your response.\n",
    "\n",
    "    You have access to the following tools:\n",
    "    {tool_names}\n",
    "    \"\"\"\n",
    "\n",
    "    user_message_content = f\"\"\" Here are the policy questions: \\n{policy_qs}\"\"\"\n",
    "    messages = [\n",
    "        {\"role\": \"system\", \"content\": system_message},\n",
    "        {\"role\": \"user\", \"content\": user_message_content}\n",
    "    ]\n",
    "\n",
    "    # model_agent = ChatOpenAI(temperature=0, model=modelID_agent)\n",
    "\n",
    "    react_agent = create_react_agent(model_agent, tools, debug=False)    \n",
    "\n",
    "    messages = react_agent.invoke({\"messages\": messages})    \n",
    "    result = messages[\"messages\"][-1].content    \n",
    "    return result"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[32;1m\u001b[1;3m[chain/start]\u001b[0m \u001b[1m[chain:LangGraph] Entering Chain run with input:\n",
      "\u001b[0m{\n",
      "  \"messages\": [\n",
      "    {\n",
      "      \"role\": \"system\",\n",
      "      \"content\": \"\\n    You are a Principal Investigator (PI) for evaluating patients for clinical trials.\\n    You are asked to compare the patient profile document to the institution policy questions.\\n    You must determine if the patient is eligible based on the following documnents.\\n\\n    \\n #### Here is the patient profile document: \\n This is a 72-year-old patient with a history of hypertension.  The patient has not participated in any previous clinical trials.  Given their age and medical history, they may be eligible for trials investigating new treatments for hypertension management or age-related cardiovascular diseases.  \\n\\n\\n**Suggested Trials:**\\n\\n* **Trials focusing on new antihypertensive medications:**  These trials often seek participants with uncontrolled hypertension.\\n* **Trials investigating lifestyle interventions for hypertension:**  These trials may target older adults and focus on diet, exercise, or stress management.\\n* **Trials exploring the impact of hypertension on other age-related conditions:**  This could include trials looking at the relationship between hypertension and cognitive decline or heart failure. \\n\\n\\n\\n\\n\\n    If the answer to any policy question is yes, then the patient is not eligible.\\n\\n    If the answer to the question is not provided in the patient profile, answer 'no'.\\n\\n\\n    Give a binary 'yes' or 'no' score in the response to indicate whether the patient is eligible according to the given policy ONLY.\\n    If the patient is not eligible then also include the reason in your response.\\n\\n    You have access to the following tools:\\n    multiply, date_today-tool, date_difference, date_split-tool, number_comparison-tool\\n    \"\n",
      "    },\n",
      "    {\n",
      "      \"role\": \"user\",\n",
      "      \"content\": \" Here are the policy questions: \\n\\n        Key Inclusion Criteria:\\r\\n\\r\\n          -  Subject must be ≥18 years of age.\\r\\n\\r\\n          -  Subjects must have documented IDH1 R132 gene-mutated advanced hematologic malignancy\\r\\n             based on local or central evaluation.\\r\\n\\r\\n          -  Subjects must be amenable to serial bone marrow biopsies, peripheral blood sampling,\\r\\n             and urine sampling during the study.\\r\\n\\r\\n          -  Subjects must have ECOG PS of 0 to 2.\\r\\n\\r\\n          -  Platelet count ≥20,000/µL (Transfusions to achieve this level are allowed).\\r\\n\\r\\n          -  Subjects must have adequate hepatic function as evidenced by: Aspartate\\r\\n             aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP)\\r\\n             ≤3.0 × ULN, unless considered due to leukemic disease and serum total bilirubin ≤1.5 x\\r\\n             upper limit of normal (ULN), unless considered due to Gilbert's disease or leukemic\\r\\n             disease\\r\\n\\r\\n          -  Subjects must have adequate renal function as evidenced by a serum creatinine ≤2.0 ×\\r\\n             ULN or creatinine clearance >40mL/min based on Cockroft-Gault glomerular filtration\\r\\n             rate (GFR)\\r\\n\\r\\n          -  Subjects must be recovered from any clinically relevant toxic effects of any prior\\r\\n             surgery, radiotherapy, or other therapy intended for the treatment of cancer.\\r\\n\\r\\n          -  Female subjects with reproductive potential must have a negative serum pregnancy test\\r\\n             within 7 days prior to the start of therapy and on the first day of study drug\\r\\n             administration.\\r\\n\\r\\n        Key Exclusion Criteria:\\r\\n\\r\\n          -  Subjects who have undergone hematopoietic stem cell transplant (HSCT) within 60 days\\r\\n             of the first dose of AG-120, or subjects on immunosuppressive therapy post HSCT at the\\r\\n             time of screening, or with clinically significant graft-versus-host disease (GVHD).\\r\\n             (The use of a stable dose of oral steroids post HSCT and/or topical for ongoing skin\\r\\n             GVHD is permitted.)\\r\\n\\r\\n          -  Subjects who received systemic anticancer therapy or radiotherapy <14 days prior to\\r\\n             their first day of study drug administration. (Hydroxyurea is allowed prior to\\r\\n             enrollment and after the start of AG-120).\\r\\n\\r\\n          -  Subjects who received an investigational agent <14 days prior to their first day of\\r\\n             study drug administration.\\r\\n\\r\\n          -  Subjects who are pregnant or breastfeeding.\\r\\n\\r\\n          -  Subjects with an active severe infection or with an unexplained fever >38.5°C during\\r\\n             screening visits or on their first day of study drug administration (at the discretion\\r\\n             of the Investigator, subjects with tumor fever may be enrolled).\\r\\n\\r\\n          -  Subjects with New York Heart Association (NYHA) Class III or IV congestive heart\\r\\n             failure or LVEF <40% by echocardiogram (ECHO) or multi-gated acquisition (MUGA) scan\\r\\n             within approximately 28 days of C1D1.\\r\\n\\r\\n          -  Subjects with a history of myocardial infarction within the last 6 months of\\r\\n             screening.\\r\\n\\r\\n          -  Subjects with a known unstable or uncontrolled angina pectoris.\\r\\n\\r\\n          -  Subjects with a known history of severe and/or uncontrolled ventricular arrhythmias.\\r\\n\\r\\n          -  Subjects with known unstable or uncontrolled angina pectoris.\\r\\n\\r\\n          -  Subjects with heart-rate corrected QT (QTc) interval ≥450 ms or other factors that\\r\\n             increase the risk of QT prolongation or arrhythmic events.\\r\\n\\r\\n          -  Patients taking medications that are known to prolong the QT interval\\r\\n\\r\\n          -  Subjects with known infection with human immunodeficiency virus (HIV) or active\\r\\n             hepatitis B or C.\\r\\n\\r\\n          -  Subjects with clinical symptoms suggesting active central nervous system (CNS)\\r\\n             leukemia or known CNS leukemia. Evaluation of cerebrospinal fluid is only required if\\r\\n             there is a clinical suspicion of CNS involvement by leukemia during screening.\\r\\n\\r\\n          -  Subjects with immediately life-threatening, severe complications of leukemia such as\\r\\n             uncontrolled bleeding, pneumonia with hypoxia or shock, and/or disseminated\\r\\n             intravascular coagulation.\\r\\n      \"\n",
      "    }\n",
      "  ]\n",
      "}\n",
      "\u001b[32;1m\u001b[1;3m[chain/start]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent] Entering Chain run with input:\n",
      "\u001b[0m[inputs]\n",
      "\u001b[32;1m\u001b[1;3m[chain/start]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent > chain:call_model] Entering Chain run with input:\n",
      "\u001b[0m[inputs]\n",
      "\u001b[32;1m\u001b[1;3m[chain/start]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent > chain:call_model > chain:RunnableSequence] Entering Chain run with input:\n",
      "\u001b[0m[inputs]\n",
      "\u001b[32;1m\u001b[1;3m[chain/start]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent > chain:call_model > chain:RunnableSequence > chain:Prompt] Entering Chain run with input:\n",
      "\u001b[0m[inputs]\n",
      "\u001b[36;1m\u001b[1;3m[chain/end]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent > chain:call_model > chain:RunnableSequence > chain:Prompt] [1ms] Exiting Chain run with output:\n",
      "\u001b[0m[outputs]\n",
      "\u001b[32;1m\u001b[1;3m[llm/start]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent > chain:call_model > chain:RunnableSequence > llm:ChatGroq] Entering LLM run with input:\n",
      "\u001b[0m{\n",
      "  \"prompts\": [\n",
      "    \"System: \\n    You are a Principal Investigator (PI) for evaluating patients for clinical trials.\\n    You are asked to compare the patient profile document to the institution policy questions.\\n    You must determine if the patient is eligible based on the following documnents.\\n\\n    \\n #### Here is the patient profile document: \\n This is a 72-year-old patient with a history of hypertension.  The patient has not participated in any previous clinical trials.  Given their age and medical history, they may be eligible for trials investigating new treatments for hypertension management or age-related cardiovascular diseases.  \\n\\n\\n**Suggested Trials:**\\n\\n* **Trials focusing on new antihypertensive medications:**  These trials often seek participants with uncontrolled hypertension.\\n* **Trials investigating lifestyle interventions for hypertension:**  These trials may target older adults and focus on diet, exercise, or stress management.\\n* **Trials exploring the impact of hypertension on other age-related conditions:**  This could include trials looking at the relationship between hypertension and cognitive decline or heart failure. \\n\\n\\n\\n\\n\\n    If the answer to any policy question is yes, then the patient is not eligible.\\n\\n    If the answer to the question is not provided in the patient profile, answer 'no'.\\n\\n\\n    Give a binary 'yes' or 'no' score in the response to indicate whether the patient is eligible according to the given policy ONLY.\\n    If the patient is not eligible then also include the reason in your response.\\n\\n    You have access to the following tools:\\n    multiply, date_today-tool, date_difference, date_split-tool, number_comparison-tool\\n    \\nHuman:  Here are the policy questions: \\n\\n        Key Inclusion Criteria:\\r\\n\\r\\n          -  Subject must be ≥18 years of age.\\r\\n\\r\\n          -  Subjects must have documented IDH1 R132 gene-mutated advanced hematologic malignancy\\r\\n             based on local or central evaluation.\\r\\n\\r\\n          -  Subjects must be amenable to serial bone marrow biopsies, peripheral blood sampling,\\r\\n             and urine sampling during the study.\\r\\n\\r\\n          -  Subjects must have ECOG PS of 0 to 2.\\r\\n\\r\\n          -  Platelet count ≥20,000/µL (Transfusions to achieve this level are allowed).\\r\\n\\r\\n          -  Subjects must have adequate hepatic function as evidenced by: Aspartate\\r\\n             aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP)\\r\\n             ≤3.0 × ULN, unless considered due to leukemic disease and serum total bilirubin ≤1.5 x\\r\\n             upper limit of normal (ULN), unless considered due to Gilbert's disease or leukemic\\r\\n             disease\\r\\n\\r\\n          -  Subjects must have adequate renal function as evidenced by a serum creatinine ≤2.0 ×\\r\\n             ULN or creatinine clearance >40mL/min based on Cockroft-Gault glomerular filtration\\r\\n             rate (GFR)\\r\\n\\r\\n          -  Subjects must be recovered from any clinically relevant toxic effects of any prior\\r\\n             surgery, radiotherapy, or other therapy intended for the treatment of cancer.\\r\\n\\r\\n          -  Female subjects with reproductive potential must have a negative serum pregnancy test\\r\\n             within 7 days prior to the start of therapy and on the first day of study drug\\r\\n             administration.\\r\\n\\r\\n        Key Exclusion Criteria:\\r\\n\\r\\n          -  Subjects who have undergone hematopoietic stem cell transplant (HSCT) within 60 days\\r\\n             of the first dose of AG-120, or subjects on immunosuppressive therapy post HSCT at the\\r\\n             time of screening, or with clinically significant graft-versus-host disease (GVHD).\\r\\n             (The use of a stable dose of oral steroids post HSCT and/or topical for ongoing skin\\r\\n             GVHD is permitted.)\\r\\n\\r\\n          -  Subjects who received systemic anticancer therapy or radiotherapy <14 days prior to\\r\\n             their first day of study drug administration. (Hydroxyurea is allowed prior to\\r\\n             enrollment and after the start of AG-120).\\r\\n\\r\\n          -  Subjects who received an investigational agent <14 days prior to their first day of\\r\\n             study drug administration.\\r\\n\\r\\n          -  Subjects who are pregnant or breastfeeding.\\r\\n\\r\\n          -  Subjects with an active severe infection or with an unexplained fever >38.5°C during\\r\\n             screening visits or on their first day of study drug administration (at the discretion\\r\\n             of the Investigator, subjects with tumor fever may be enrolled).\\r\\n\\r\\n          -  Subjects with New York Heart Association (NYHA) Class III or IV congestive heart\\r\\n             failure or LVEF <40% by echocardiogram (ECHO) or multi-gated acquisition (MUGA) scan\\r\\n             within approximately 28 days of C1D1.\\r\\n\\r\\n          -  Subjects with a history of myocardial infarction within the last 6 months of\\r\\n             screening.\\r\\n\\r\\n          -  Subjects with a known unstable or uncontrolled angina pectoris.\\r\\n\\r\\n          -  Subjects with a known history of severe and/or uncontrolled ventricular arrhythmias.\\r\\n\\r\\n          -  Subjects with known unstable or uncontrolled angina pectoris.\\r\\n\\r\\n          -  Subjects with heart-rate corrected QT (QTc) interval ≥450 ms or other factors that\\r\\n             increase the risk of QT prolongation or arrhythmic events.\\r\\n\\r\\n          -  Patients taking medications that are known to prolong the QT interval\\r\\n\\r\\n          -  Subjects with known infection with human immunodeficiency virus (HIV) or active\\r\\n             hepatitis B or C.\\r\\n\\r\\n          -  Subjects with clinical symptoms suggesting active central nervous system (CNS)\\r\\n             leukemia or known CNS leukemia. Evaluation of cerebrospinal fluid is only required if\\r\\n             there is a clinical suspicion of CNS involvement by leukemia during screening.\\r\\n\\r\\n          -  Subjects with immediately life-threatening, severe complications of leukemia such as\\r\\n             uncontrolled bleeding, pneumonia with hypoxia or shock, and/or disseminated\\r\\n             intravascular coagulation.\"\n",
      "  ]\n",
      "}\n",
      "\u001b[36;1m\u001b[1;3m[llm/end]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent > chain:call_model > chain:RunnableSequence > llm:ChatGroq] [552ms] Exiting LLM run with output:\n",
      "\u001b[0m{\n",
      "  \"generations\": [\n",
      "    [\n",
      "      {\n",
      "        \"text\": \"\",\n",
      "        \"generation_info\": {\n",
      "          \"finish_reason\": \"tool_calls\",\n",
      "          \"logprobs\": null\n",
      "        },\n",
      "        \"type\": \"ChatGeneration\",\n",
      "        \"message\": {\n",
      "          \"lc\": 1,\n",
      "          \"type\": \"constructor\",\n",
      "          \"id\": [\n",
      "            \"langchain\",\n",
      "            \"schema\",\n",
      "            \"messages\",\n",
      "            \"AIMessage\"\n",
      "          ],\n",
      "          \"kwargs\": {\n",
      "            \"content\": \"\",\n",
      "            \"additional_kwargs\": {\n",
      "              \"tool_calls\": [\n",
      "                {\n",
      "                  \"id\": \"sbgaf4bkb\",\n",
      "                  \"function\": {\n",
      "                    \"arguments\": \"{\\\"num1\\\":72,\\\"num2\\\":18}\",\n",
      "                    \"name\": \"number_comparison-tool\"\n",
      "                  },\n",
      "                  \"type\": \"function\"\n",
      "                }\n",
      "              ]\n",
      "            },\n",
      "            \"response_metadata\": {\n",
      "              \"token_usage\": {\n",
      "                \"completion_tokens\": 95,\n",
      "                \"prompt_tokens\": 2792,\n",
      "                \"total_tokens\": 2887,\n",
      "                \"completion_time\": 0.172727273,\n",
      "                \"prompt_time\": 0.052346207,\n",
      "                \"queue_time\": 0.196090563,\n",
      "                \"total_time\": 0.22507348\n",
      "              },\n",
      "              \"model_name\": \"gemma2-9b-it\",\n",
      "              \"system_fingerprint\": \"fp_10c08bf97d\",\n",
      "              \"service_tier\": \"on_demand\",\n",
      "              \"finish_reason\": \"tool_calls\",\n",
      "              \"logprobs\": null\n",
      "            },\n",
      "            \"type\": \"ai\",\n",
      "            \"id\": \"run--ec0d471d-76b6-4a72-b687-bd68f34b1659-0\",\n",
      "            \"tool_calls\": [\n",
      "              {\n",
      "                \"name\": \"number_comparison-tool\",\n",
      "                \"args\": {\n",
      "                  \"num1\": 72,\n",
      "                  \"num2\": 18\n",
      "                },\n",
      "                \"id\": \"sbgaf4bkb\",\n",
      "                \"type\": \"tool_call\"\n",
      "              }\n",
      "            ],\n",
      "            \"usage_metadata\": {\n",
      "              \"input_tokens\": 2792,\n",
      "              \"output_tokens\": 95,\n",
      "              \"total_tokens\": 2887\n",
      "            },\n",
      "            \"invalid_tool_calls\": []\n",
      "          }\n",
      "        }\n",
      "      }\n",
      "    ]\n",
      "  ],\n",
      "  \"llm_output\": {\n",
      "    \"token_usage\": {\n",
      "      \"completion_tokens\": 95,\n",
      "      \"prompt_tokens\": 2792,\n",
      "      \"total_tokens\": 2887,\n",
      "      \"completion_time\": 0.172727273,\n",
      "      \"prompt_time\": 0.052346207,\n",
      "      \"queue_time\": 0.196090563,\n",
      "      \"total_time\": 0.22507348\n",
      "    },\n",
      "    \"model_name\": \"gemma2-9b-it\",\n",
      "    \"system_fingerprint\": \"fp_10c08bf97d\",\n",
      "    \"service_tier\": \"on_demand\"\n",
      "  },\n",
      "  \"run\": null,\n",
      "  \"type\": \"LLMResult\"\n",
      "}\n",
      "\u001b[36;1m\u001b[1;3m[chain/end]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent > chain:call_model > chain:RunnableSequence] [554ms] Exiting Chain run with output:\n",
      "\u001b[0m[outputs]\n",
      "\u001b[36;1m\u001b[1;3m[chain/end]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent > chain:call_model] [554ms] Exiting Chain run with output:\n",
      "\u001b[0m[outputs]\n",
      "\u001b[32;1m\u001b[1;3m[chain/start]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent > chain:should_continue] Entering Chain run with input:\n",
      "\u001b[0m[inputs]\n",
      "\u001b[36;1m\u001b[1;3m[chain/end]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent > chain:should_continue] [1ms] Exiting Chain run with output:\n",
      "\u001b[0m{\n",
      "  \"output\": \"tools\"\n",
      "}\n",
      "\u001b[36;1m\u001b[1;3m[chain/end]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent] [556ms] Exiting Chain run with output:\n",
      "\u001b[0m[outputs]\n",
      "\u001b[32;1m\u001b[1;3m[chain/start]\u001b[0m \u001b[1m[chain:LangGraph > chain:tools] Entering Chain run with input:\n",
      "\u001b[0m[inputs]\n",
      "\u001b[32;1m\u001b[1;3m[tool/start]\u001b[0m \u001b[1m[chain:LangGraph > chain:tools > tool:number_comparison-tool] Entering Tool run with input:\n",
      "\u001b[0m\"{'num1': 72, 'num2': 18}\"\n",
      "\u001b[36;1m\u001b[1;3m[tool/end]\u001b[0m \u001b[1m[chain:LangGraph > chain:tools > tool:number_comparison-tool] [1ms] Exiting Tool run with output:\n",
      "\u001b[0m\"content='false' name='number_comparison-tool' tool_call_id='sbgaf4bkb'\"\n",
      "\u001b[36;1m\u001b[1;3m[chain/end]\u001b[0m \u001b[1m[chain:LangGraph > chain:tools] [2ms] Exiting Chain run with output:\n",
      "\u001b[0m[outputs]\n",
      "\u001b[32;1m\u001b[1;3m[chain/start]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent] Entering Chain run with input:\n",
      "\u001b[0m[inputs]\n",
      "\u001b[32;1m\u001b[1;3m[chain/start]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent > chain:call_model] Entering Chain run with input:\n",
      "\u001b[0m[inputs]\n",
      "\u001b[32;1m\u001b[1;3m[chain/start]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent > chain:call_model > chain:RunnableSequence] Entering Chain run with input:\n",
      "\u001b[0m[inputs]\n",
      "\u001b[32;1m\u001b[1;3m[chain/start]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent > chain:call_model > chain:RunnableSequence > chain:Prompt] Entering Chain run with input:\n",
      "\u001b[0m[inputs]\n",
      "\u001b[36;1m\u001b[1;3m[chain/end]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent > chain:call_model > chain:RunnableSequence > chain:Prompt] [0ms] Exiting Chain run with output:\n",
      "\u001b[0m[outputs]\n",
      "\u001b[32;1m\u001b[1;3m[llm/start]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent > chain:call_model > chain:RunnableSequence > llm:ChatGroq] Entering LLM run with input:\n",
      "\u001b[0m{\n",
      "  \"prompts\": [\n",
      "    \"System: \\n    You are a Principal Investigator (PI) for evaluating patients for clinical trials.\\n    You are asked to compare the patient profile document to the institution policy questions.\\n    You must determine if the patient is eligible based on the following documnents.\\n\\n    \\n #### Here is the patient profile document: \\n This is a 72-year-old patient with a history of hypertension.  The patient has not participated in any previous clinical trials.  Given their age and medical history, they may be eligible for trials investigating new treatments for hypertension management or age-related cardiovascular diseases.  \\n\\n\\n**Suggested Trials:**\\n\\n* **Trials focusing on new antihypertensive medications:**  These trials often seek participants with uncontrolled hypertension.\\n* **Trials investigating lifestyle interventions for hypertension:**  These trials may target older adults and focus on diet, exercise, or stress management.\\n* **Trials exploring the impact of hypertension on other age-related conditions:**  This could include trials looking at the relationship between hypertension and cognitive decline or heart failure. \\n\\n\\n\\n\\n\\n    If the answer to any policy question is yes, then the patient is not eligible.\\n\\n    If the answer to the question is not provided in the patient profile, answer 'no'.\\n\\n\\n    Give a binary 'yes' or 'no' score in the response to indicate whether the patient is eligible according to the given policy ONLY.\\n    If the patient is not eligible then also include the reason in your response.\\n\\n    You have access to the following tools:\\n    multiply, date_today-tool, date_difference, date_split-tool, number_comparison-tool\\n    \\nHuman:  Here are the policy questions: \\n\\n        Key Inclusion Criteria:\\r\\n\\r\\n          -  Subject must be ≥18 years of age.\\r\\n\\r\\n          -  Subjects must have documented IDH1 R132 gene-mutated advanced hematologic malignancy\\r\\n             based on local or central evaluation.\\r\\n\\r\\n          -  Subjects must be amenable to serial bone marrow biopsies, peripheral blood sampling,\\r\\n             and urine sampling during the study.\\r\\n\\r\\n          -  Subjects must have ECOG PS of 0 to 2.\\r\\n\\r\\n          -  Platelet count ≥20,000/µL (Transfusions to achieve this level are allowed).\\r\\n\\r\\n          -  Subjects must have adequate hepatic function as evidenced by: Aspartate\\r\\n             aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP)\\r\\n             ≤3.0 × ULN, unless considered due to leukemic disease and serum total bilirubin ≤1.5 x\\r\\n             upper limit of normal (ULN), unless considered due to Gilbert's disease or leukemic\\r\\n             disease\\r\\n\\r\\n          -  Subjects must have adequate renal function as evidenced by a serum creatinine ≤2.0 ×\\r\\n             ULN or creatinine clearance >40mL/min based on Cockroft-Gault glomerular filtration\\r\\n             rate (GFR)\\r\\n\\r\\n          -  Subjects must be recovered from any clinically relevant toxic effects of any prior\\r\\n             surgery, radiotherapy, or other therapy intended for the treatment of cancer.\\r\\n\\r\\n          -  Female subjects with reproductive potential must have a negative serum pregnancy test\\r\\n             within 7 days prior to the start of therapy and on the first day of study drug\\r\\n             administration.\\r\\n\\r\\n        Key Exclusion Criteria:\\r\\n\\r\\n          -  Subjects who have undergone hematopoietic stem cell transplant (HSCT) within 60 days\\r\\n             of the first dose of AG-120, or subjects on immunosuppressive therapy post HSCT at the\\r\\n             time of screening, or with clinically significant graft-versus-host disease (GVHD).\\r\\n             (The use of a stable dose of oral steroids post HSCT and/or topical for ongoing skin\\r\\n             GVHD is permitted.)\\r\\n\\r\\n          -  Subjects who received systemic anticancer therapy or radiotherapy <14 days prior to\\r\\n             their first day of study drug administration. (Hydroxyurea is allowed prior to\\r\\n             enrollment and after the start of AG-120).\\r\\n\\r\\n          -  Subjects who received an investigational agent <14 days prior to their first day of\\r\\n             study drug administration.\\r\\n\\r\\n          -  Subjects who are pregnant or breastfeeding.\\r\\n\\r\\n          -  Subjects with an active severe infection or with an unexplained fever >38.5°C during\\r\\n             screening visits or on their first day of study drug administration (at the discretion\\r\\n             of the Investigator, subjects with tumor fever may be enrolled).\\r\\n\\r\\n          -  Subjects with New York Heart Association (NYHA) Class III or IV congestive heart\\r\\n             failure or LVEF <40% by echocardiogram (ECHO) or multi-gated acquisition (MUGA) scan\\r\\n             within approximately 28 days of C1D1.\\r\\n\\r\\n          -  Subjects with a history of myocardial infarction within the last 6 months of\\r\\n             screening.\\r\\n\\r\\n          -  Subjects with a known unstable or uncontrolled angina pectoris.\\r\\n\\r\\n          -  Subjects with a known history of severe and/or uncontrolled ventricular arrhythmias.\\r\\n\\r\\n          -  Subjects with known unstable or uncontrolled angina pectoris.\\r\\n\\r\\n          -  Subjects with heart-rate corrected QT (QTc) interval ≥450 ms or other factors that\\r\\n             increase the risk of QT prolongation or arrhythmic events.\\r\\n\\r\\n          -  Patients taking medications that are known to prolong the QT interval\\r\\n\\r\\n          -  Subjects with known infection with human immunodeficiency virus (HIV) or active\\r\\n             hepatitis B or C.\\r\\n\\r\\n          -  Subjects with clinical symptoms suggesting active central nervous system (CNS)\\r\\n             leukemia or known CNS leukemia. Evaluation of cerebrospinal fluid is only required if\\r\\n             there is a clinical suspicion of CNS involvement by leukemia during screening.\\r\\n\\r\\n          -  Subjects with immediately life-threatening, severe complications of leukemia such as\\r\\n             uncontrolled bleeding, pneumonia with hypoxia or shock, and/or disseminated\\r\\n             intravascular coagulation.\\r\\n      \\nAI: \\nTool: false\"\n",
      "  ]\n",
      "}\n",
      "\u001b[36;1m\u001b[1;3m[llm/end]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent > chain:call_model > chain:RunnableSequence > llm:ChatGroq] [364ms] Exiting LLM run with output:\n",
      "\u001b[0m{\n",
      "  \"generations\": [\n",
      "    [\n",
      "      {\n",
      "        \"text\": \"\",\n",
      "        \"generation_info\": {\n",
      "          \"finish_reason\": \"tool_calls\",\n",
      "          \"logprobs\": null\n",
      "        },\n",
      "        \"type\": \"ChatGeneration\",\n",
      "        \"message\": {\n",
      "          \"lc\": 1,\n",
      "          \"type\": \"constructor\",\n",
      "          \"id\": [\n",
      "            \"langchain\",\n",
      "            \"schema\",\n",
      "            \"messages\",\n",
      "            \"AIMessage\"\n",
      "          ],\n",
      "          \"kwargs\": {\n",
      "            \"content\": \"\",\n",
      "            \"additional_kwargs\": {\n",
      "              \"tool_calls\": [\n",
      "                {\n",
      "                  \"id\": \"mfh6ryc9q\",\n",
      "                  \"function\": {\n",
      "                    \"arguments\": \"{}\",\n",
      "                    \"name\": \"date_today-tool\"\n",
      "                  },\n",
      "                  \"type\": \"function\"\n",
      "                }\n",
      "              ]\n",
      "            },\n",
      "            \"response_metadata\": {\n",
      "              \"token_usage\": {\n",
      "                \"completion_tokens\": 38,\n",
      "                \"prompt_tokens\": 2872,\n",
      "                \"total_tokens\": 2910,\n",
      "                \"completion_time\": 0.069090909,\n",
      "                \"prompt_time\": 0.059677774,\n",
      "                \"queue_time\": 0.197647729,\n",
      "                \"total_time\": 0.128768683\n",
      "              },\n",
      "              \"model_name\": \"gemma2-9b-it\",\n",
      "              \"system_fingerprint\": \"fp_10c08bf97d\",\n",
      "              \"service_tier\": \"on_demand\",\n",
      "              \"finish_reason\": \"tool_calls\",\n",
      "              \"logprobs\": null\n",
      "            },\n",
      "            \"type\": \"ai\",\n",
      "            \"id\": \"run--b3fb11e1-7ee1-44de-8959-ae3c9dda6a4d-0\",\n",
      "            \"tool_calls\": [\n",
      "              {\n",
      "                \"name\": \"date_today-tool\",\n",
      "                \"args\": {},\n",
      "                \"id\": \"mfh6ryc9q\",\n",
      "                \"type\": \"tool_call\"\n",
      "              }\n",
      "            ],\n",
      "            \"usage_metadata\": {\n",
      "              \"input_tokens\": 2872,\n",
      "              \"output_tokens\": 38,\n",
      "              \"total_tokens\": 2910\n",
      "            },\n",
      "            \"invalid_tool_calls\": []\n",
      "          }\n",
      "        }\n",
      "      }\n",
      "    ]\n",
      "  ],\n",
      "  \"llm_output\": {\n",
      "    \"token_usage\": {\n",
      "      \"completion_tokens\": 38,\n",
      "      \"prompt_tokens\": 2872,\n",
      "      \"total_tokens\": 2910,\n",
      "      \"completion_time\": 0.069090909,\n",
      "      \"prompt_time\": 0.059677774,\n",
      "      \"queue_time\": 0.197647729,\n",
      "      \"total_time\": 0.128768683\n",
      "    },\n",
      "    \"model_name\": \"gemma2-9b-it\",\n",
      "    \"system_fingerprint\": \"fp_10c08bf97d\",\n",
      "    \"service_tier\": \"on_demand\"\n",
      "  },\n",
      "  \"run\": null,\n",
      "  \"type\": \"LLMResult\"\n",
      "}\n",
      "\u001b[36;1m\u001b[1;3m[chain/end]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent > chain:call_model > chain:RunnableSequence] [367ms] Exiting Chain run with output:\n",
      "\u001b[0m[outputs]\n",
      "\u001b[36;1m\u001b[1;3m[chain/end]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent > chain:call_model] [368ms] Exiting Chain run with output:\n",
      "\u001b[0m[outputs]\n",
      "\u001b[32;1m\u001b[1;3m[chain/start]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent > chain:should_continue] Entering Chain run with input:\n",
      "\u001b[0m[inputs]\n",
      "\u001b[36;1m\u001b[1;3m[chain/end]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent > chain:should_continue] [1ms] Exiting Chain run with output:\n",
      "\u001b[0m{\n",
      "  \"output\": \"tools\"\n",
      "}\n",
      "\u001b[36;1m\u001b[1;3m[chain/end]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent] [370ms] Exiting Chain run with output:\n",
      "\u001b[0m[outputs]\n",
      "\u001b[32;1m\u001b[1;3m[chain/start]\u001b[0m \u001b[1m[chain:LangGraph > chain:tools] Entering Chain run with input:\n",
      "\u001b[0m[inputs]\n",
      "\u001b[32;1m\u001b[1;3m[tool/start]\u001b[0m \u001b[1m[chain:LangGraph > chain:tools > tool:date_today-tool] Entering Tool run with input:\n",
      "\u001b[0m\"{}\"\n",
      "\u001b[36;1m\u001b[1;3m[tool/end]\u001b[0m \u001b[1m[chain:LangGraph > chain:tools > tool:date_today-tool] [1ms] Exiting Tool run with output:\n",
      "\u001b[0m\"content='2025-07-20' name='date_today-tool' tool_call_id='mfh6ryc9q'\"\n",
      "\u001b[36;1m\u001b[1;3m[chain/end]\u001b[0m \u001b[1m[chain:LangGraph > chain:tools] [2ms] Exiting Chain run with output:\n",
      "\u001b[0m[outputs]\n",
      "\u001b[32;1m\u001b[1;3m[chain/start]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent] Entering Chain run with input:\n",
      "\u001b[0m[inputs]\n",
      "\u001b[32;1m\u001b[1;3m[chain/start]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent > chain:call_model] Entering Chain run with input:\n",
      "\u001b[0m[inputs]\n",
      "\u001b[32;1m\u001b[1;3m[chain/start]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent > chain:call_model > chain:RunnableSequence] Entering Chain run with input:\n",
      "\u001b[0m[inputs]\n",
      "\u001b[32;1m\u001b[1;3m[chain/start]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent > chain:call_model > chain:RunnableSequence > chain:Prompt] Entering Chain run with input:\n",
      "\u001b[0m[inputs]\n",
      "\u001b[36;1m\u001b[1;3m[chain/end]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent > chain:call_model > chain:RunnableSequence > chain:Prompt] [0ms] Exiting Chain run with output:\n",
      "\u001b[0m[outputs]\n",
      "\u001b[32;1m\u001b[1;3m[llm/start]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent > chain:call_model > chain:RunnableSequence > llm:ChatGroq] Entering LLM run with input:\n",
      "\u001b[0m{\n",
      "  \"prompts\": [\n",
      "    \"System: \\n    You are a Principal Investigator (PI) for evaluating patients for clinical trials.\\n    You are asked to compare the patient profile document to the institution policy questions.\\n    You must determine if the patient is eligible based on the following documnents.\\n\\n    \\n #### Here is the patient profile document: \\n This is a 72-year-old patient with a history of hypertension.  The patient has not participated in any previous clinical trials.  Given their age and medical history, they may be eligible for trials investigating new treatments for hypertension management or age-related cardiovascular diseases.  \\n\\n\\n**Suggested Trials:**\\n\\n* **Trials focusing on new antihypertensive medications:**  These trials often seek participants with uncontrolled hypertension.\\n* **Trials investigating lifestyle interventions for hypertension:**  These trials may target older adults and focus on diet, exercise, or stress management.\\n* **Trials exploring the impact of hypertension on other age-related conditions:**  This could include trials looking at the relationship between hypertension and cognitive decline or heart failure. \\n\\n\\n\\n\\n\\n    If the answer to any policy question is yes, then the patient is not eligible.\\n\\n    If the answer to the question is not provided in the patient profile, answer 'no'.\\n\\n\\n    Give a binary 'yes' or 'no' score in the response to indicate whether the patient is eligible according to the given policy ONLY.\\n    If the patient is not eligible then also include the reason in your response.\\n\\n    You have access to the following tools:\\n    multiply, date_today-tool, date_difference, date_split-tool, number_comparison-tool\\n    \\nHuman:  Here are the policy questions: \\n\\n        Key Inclusion Criteria:\\r\\n\\r\\n          -  Subject must be ≥18 years of age.\\r\\n\\r\\n          -  Subjects must have documented IDH1 R132 gene-mutated advanced hematologic malignancy\\r\\n             based on local or central evaluation.\\r\\n\\r\\n          -  Subjects must be amenable to serial bone marrow biopsies, peripheral blood sampling,\\r\\n             and urine sampling during the study.\\r\\n\\r\\n          -  Subjects must have ECOG PS of 0 to 2.\\r\\n\\r\\n          -  Platelet count ≥20,000/µL (Transfusions to achieve this level are allowed).\\r\\n\\r\\n          -  Subjects must have adequate hepatic function as evidenced by: Aspartate\\r\\n             aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP)\\r\\n             ≤3.0 × ULN, unless considered due to leukemic disease and serum total bilirubin ≤1.5 x\\r\\n             upper limit of normal (ULN), unless considered due to Gilbert's disease or leukemic\\r\\n             disease\\r\\n\\r\\n          -  Subjects must have adequate renal function as evidenced by a serum creatinine ≤2.0 ×\\r\\n             ULN or creatinine clearance >40mL/min based on Cockroft-Gault glomerular filtration\\r\\n             rate (GFR)\\r\\n\\r\\n          -  Subjects must be recovered from any clinically relevant toxic effects of any prior\\r\\n             surgery, radiotherapy, or other therapy intended for the treatment of cancer.\\r\\n\\r\\n          -  Female subjects with reproductive potential must have a negative serum pregnancy test\\r\\n             within 7 days prior to the start of therapy and on the first day of study drug\\r\\n             administration.\\r\\n\\r\\n        Key Exclusion Criteria:\\r\\n\\r\\n          -  Subjects who have undergone hematopoietic stem cell transplant (HSCT) within 60 days\\r\\n             of the first dose of AG-120, or subjects on immunosuppressive therapy post HSCT at the\\r\\n             time of screening, or with clinically significant graft-versus-host disease (GVHD).\\r\\n             (The use of a stable dose of oral steroids post HSCT and/or topical for ongoing skin\\r\\n             GVHD is permitted.)\\r\\n\\r\\n          -  Subjects who received systemic anticancer therapy or radiotherapy <14 days prior to\\r\\n             their first day of study drug administration. (Hydroxyurea is allowed prior to\\r\\n             enrollment and after the start of AG-120).\\r\\n\\r\\n          -  Subjects who received an investigational agent <14 days prior to their first day of\\r\\n             study drug administration.\\r\\n\\r\\n          -  Subjects who are pregnant or breastfeeding.\\r\\n\\r\\n          -  Subjects with an active severe infection or with an unexplained fever >38.5°C during\\r\\n             screening visits or on their first day of study drug administration (at the discretion\\r\\n             of the Investigator, subjects with tumor fever may be enrolled).\\r\\n\\r\\n          -  Subjects with New York Heart Association (NYHA) Class III or IV congestive heart\\r\\n             failure or LVEF <40% by echocardiogram (ECHO) or multi-gated acquisition (MUGA) scan\\r\\n             within approximately 28 days of C1D1.\\r\\n\\r\\n          -  Subjects with a history of myocardial infarction within the last 6 months of\\r\\n             screening.\\r\\n\\r\\n          -  Subjects with a known unstable or uncontrolled angina pectoris.\\r\\n\\r\\n          -  Subjects with a known history of severe and/or uncontrolled ventricular arrhythmias.\\r\\n\\r\\n          -  Subjects with known unstable or uncontrolled angina pectoris.\\r\\n\\r\\n          -  Subjects with heart-rate corrected QT (QTc) interval ≥450 ms or other factors that\\r\\n             increase the risk of QT prolongation or arrhythmic events.\\r\\n\\r\\n          -  Patients taking medications that are known to prolong the QT interval\\r\\n\\r\\n          -  Subjects with known infection with human immunodeficiency virus (HIV) or active\\r\\n             hepatitis B or C.\\r\\n\\r\\n          -  Subjects with clinical symptoms suggesting active central nervous system (CNS)\\r\\n             leukemia or known CNS leukemia. Evaluation of cerebrospinal fluid is only required if\\r\\n             there is a clinical suspicion of CNS involvement by leukemia during screening.\\r\\n\\r\\n          -  Subjects with immediately life-threatening, severe complications of leukemia such as\\r\\n             uncontrolled bleeding, pneumonia with hypoxia or shock, and/or disseminated\\r\\n             intravascular coagulation.\\r\\n      \\nAI: \\nTool: false\\nAI: \\nTool: 2025-07-20\"\n",
      "  ]\n",
      "}\n",
      "\u001b[36;1m\u001b[1;3m[llm/end]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent > chain:call_model > chain:RunnableSequence > llm:ChatGroq] [405ms] Exiting LLM run with output:\n",
      "\u001b[0m{\n",
      "  \"generations\": [\n",
      "    [\n",
      "      {\n",
      "        \"text\": \"\",\n",
      "        \"generation_info\": {\n",
      "          \"finish_reason\": \"tool_calls\",\n",
      "          \"logprobs\": null\n",
      "        },\n",
      "        \"type\": \"ChatGeneration\",\n",
      "        \"message\": {\n",
      "          \"lc\": 1,\n",
      "          \"type\": \"constructor\",\n",
      "          \"id\": [\n",
      "            \"langchain\",\n",
      "            \"schema\",\n",
      "            \"messages\",\n",
      "            \"AIMessage\"\n",
      "          ],\n",
      "          \"kwargs\": {\n",
      "            \"content\": \"\",\n",
      "            \"additional_kwargs\": {\n",
      "              \"tool_calls\": [\n",
      "                {\n",
      "                  \"id\": \"4e7ewknwh\",\n",
      "                  \"function\": {\n",
      "                    \"arguments\": \"{\\\"date\\\":\\\"2025-07-20\\\"}\",\n",
      "                    \"name\": \"date_split-tool\"\n",
      "                  },\n",
      "                  \"type\": \"function\"\n",
      "                }\n",
      "              ]\n",
      "            },\n",
      "            \"response_metadata\": {\n",
      "              \"token_usage\": {\n",
      "                \"completion_tokens\": 61,\n",
      "                \"prompt_tokens\": 2955,\n",
      "                \"total_tokens\": 3016,\n",
      "                \"completion_time\": 0.110909091,\n",
      "                \"prompt_time\": 0.055377926,\n",
      "                \"queue_time\": 0.197254405,\n",
      "                \"total_time\": 0.166287017\n",
      "              },\n",
      "              \"model_name\": \"gemma2-9b-it\",\n",
      "              \"system_fingerprint\": \"fp_10c08bf97d\",\n",
      "              \"service_tier\": \"on_demand\",\n",
      "              \"finish_reason\": \"tool_calls\",\n",
      "              \"logprobs\": null\n",
      "            },\n",
      "            \"type\": \"ai\",\n",
      "            \"id\": \"run--d0507251-07e8-4e8a-a18c-c51e15fd0ddf-0\",\n",
      "            \"tool_calls\": [\n",
      "              {\n",
      "                \"name\": \"date_split-tool\",\n",
      "                \"args\": {\n",
      "                  \"date\": \"2025-07-20\"\n",
      "                },\n",
      "                \"id\": \"4e7ewknwh\",\n",
      "                \"type\": \"tool_call\"\n",
      "              }\n",
      "            ],\n",
      "            \"usage_metadata\": {\n",
      "              \"input_tokens\": 2955,\n",
      "              \"output_tokens\": 61,\n",
      "              \"total_tokens\": 3016\n",
      "            },\n",
      "            \"invalid_tool_calls\": []\n",
      "          }\n",
      "        }\n",
      "      }\n",
      "    ]\n",
      "  ],\n",
      "  \"llm_output\": {\n",
      "    \"token_usage\": {\n",
      "      \"completion_tokens\": 61,\n",
      "      \"prompt_tokens\": 2955,\n",
      "      \"total_tokens\": 3016,\n",
      "      \"completion_time\": 0.110909091,\n",
      "      \"prompt_time\": 0.055377926,\n",
      "      \"queue_time\": 0.197254405,\n",
      "      \"total_time\": 0.166287017\n",
      "    },\n",
      "    \"model_name\": \"gemma2-9b-it\",\n",
      "    \"system_fingerprint\": \"fp_10c08bf97d\",\n",
      "    \"service_tier\": \"on_demand\"\n",
      "  },\n",
      "  \"run\": null,\n",
      "  \"type\": \"LLMResult\"\n",
      "}\n",
      "\u001b[36;1m\u001b[1;3m[chain/end]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent > chain:call_model > chain:RunnableSequence] [407ms] Exiting Chain run with output:\n",
      "\u001b[0m[outputs]\n",
      "\u001b[36;1m\u001b[1;3m[chain/end]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent > chain:call_model] [408ms] Exiting Chain run with output:\n",
      "\u001b[0m[outputs]\n",
      "\u001b[32;1m\u001b[1;3m[chain/start]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent > chain:should_continue] Entering Chain run with input:\n",
      "\u001b[0m[inputs]\n",
      "\u001b[36;1m\u001b[1;3m[chain/end]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent > chain:should_continue] [0ms] Exiting Chain run with output:\n",
      "\u001b[0m{\n",
      "  \"output\": \"tools\"\n",
      "}\n",
      "\u001b[36;1m\u001b[1;3m[chain/end]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent] [409ms] Exiting Chain run with output:\n",
      "\u001b[0m[outputs]\n",
      "\u001b[32;1m\u001b[1;3m[chain/start]\u001b[0m \u001b[1m[chain:LangGraph > chain:tools] Entering Chain run with input:\n",
      "\u001b[0m[inputs]\n",
      "\u001b[32;1m\u001b[1;3m[tool/start]\u001b[0m \u001b[1m[chain:LangGraph > chain:tools > tool:date_split-tool] Entering Tool run with input:\n",
      "\u001b[0m\"{'date': '2025-07-20'}\"\n",
      "\u001b[36;1m\u001b[1;3m[tool/end]\u001b[0m \u001b[1m[chain:LangGraph > chain:tools > tool:date_split-tool] [1ms] Exiting Tool run with output:\n",
      "\u001b[0m\"content='year: 2025, month: 7' name='date_split-tool' tool_call_id='4e7ewknwh'\"\n",
      "\u001b[36;1m\u001b[1;3m[chain/end]\u001b[0m \u001b[1m[chain:LangGraph > chain:tools] [1ms] Exiting Chain run with output:\n",
      "\u001b[0m[outputs]\n",
      "\u001b[32;1m\u001b[1;3m[chain/start]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent] Entering Chain run with input:\n",
      "\u001b[0m[inputs]\n",
      "\u001b[32;1m\u001b[1;3m[chain/start]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent > chain:call_model] Entering Chain run with input:\n",
      "\u001b[0m[inputs]\n",
      "\u001b[32;1m\u001b[1;3m[chain/start]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent > chain:call_model > chain:RunnableSequence] Entering Chain run with input:\n",
      "\u001b[0m[inputs]\n",
      "\u001b[32;1m\u001b[1;3m[chain/start]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent > chain:call_model > chain:RunnableSequence > chain:Prompt] Entering Chain run with input:\n",
      "\u001b[0m[inputs]\n",
      "\u001b[36;1m\u001b[1;3m[chain/end]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent > chain:call_model > chain:RunnableSequence > chain:Prompt] [0ms] Exiting Chain run with output:\n",
      "\u001b[0m[outputs]\n",
      "\u001b[32;1m\u001b[1;3m[llm/start]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent > chain:call_model > chain:RunnableSequence > llm:ChatGroq] Entering LLM run with input:\n",
      "\u001b[0m{\n",
      "  \"prompts\": [\n",
      "    \"System: \\n    You are a Principal Investigator (PI) for evaluating patients for clinical trials.\\n    You are asked to compare the patient profile document to the institution policy questions.\\n    You must determine if the patient is eligible based on the following documnents.\\n\\n    \\n #### Here is the patient profile document: \\n This is a 72-year-old patient with a history of hypertension.  The patient has not participated in any previous clinical trials.  Given their age and medical history, they may be eligible for trials investigating new treatments for hypertension management or age-related cardiovascular diseases.  \\n\\n\\n**Suggested Trials:**\\n\\n* **Trials focusing on new antihypertensive medications:**  These trials often seek participants with uncontrolled hypertension.\\n* **Trials investigating lifestyle interventions for hypertension:**  These trials may target older adults and focus on diet, exercise, or stress management.\\n* **Trials exploring the impact of hypertension on other age-related conditions:**  This could include trials looking at the relationship between hypertension and cognitive decline or heart failure. \\n\\n\\n\\n\\n\\n    If the answer to any policy question is yes, then the patient is not eligible.\\n\\n    If the answer to the question is not provided in the patient profile, answer 'no'.\\n\\n\\n    Give a binary 'yes' or 'no' score in the response to indicate whether the patient is eligible according to the given policy ONLY.\\n    If the patient is not eligible then also include the reason in your response.\\n\\n    You have access to the following tools:\\n    multiply, date_today-tool, date_difference, date_split-tool, number_comparison-tool\\n    \\nHuman:  Here are the policy questions: \\n\\n        Key Inclusion Criteria:\\r\\n\\r\\n          -  Subject must be ≥18 years of age.\\r\\n\\r\\n          -  Subjects must have documented IDH1 R132 gene-mutated advanced hematologic malignancy\\r\\n             based on local or central evaluation.\\r\\n\\r\\n          -  Subjects must be amenable to serial bone marrow biopsies, peripheral blood sampling,\\r\\n             and urine sampling during the study.\\r\\n\\r\\n          -  Subjects must have ECOG PS of 0 to 2.\\r\\n\\r\\n          -  Platelet count ≥20,000/µL (Transfusions to achieve this level are allowed).\\r\\n\\r\\n          -  Subjects must have adequate hepatic function as evidenced by: Aspartate\\r\\n             aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP)\\r\\n             ≤3.0 × ULN, unless considered due to leukemic disease and serum total bilirubin ≤1.5 x\\r\\n             upper limit of normal (ULN), unless considered due to Gilbert's disease or leukemic\\r\\n             disease\\r\\n\\r\\n          -  Subjects must have adequate renal function as evidenced by a serum creatinine ≤2.0 ×\\r\\n             ULN or creatinine clearance >40mL/min based on Cockroft-Gault glomerular filtration\\r\\n             rate (GFR)\\r\\n\\r\\n          -  Subjects must be recovered from any clinically relevant toxic effects of any prior\\r\\n             surgery, radiotherapy, or other therapy intended for the treatment of cancer.\\r\\n\\r\\n          -  Female subjects with reproductive potential must have a negative serum pregnancy test\\r\\n             within 7 days prior to the start of therapy and on the first day of study drug\\r\\n             administration.\\r\\n\\r\\n        Key Exclusion Criteria:\\r\\n\\r\\n          -  Subjects who have undergone hematopoietic stem cell transplant (HSCT) within 60 days\\r\\n             of the first dose of AG-120, or subjects on immunosuppressive therapy post HSCT at the\\r\\n             time of screening, or with clinically significant graft-versus-host disease (GVHD).\\r\\n             (The use of a stable dose of oral steroids post HSCT and/or topical for ongoing skin\\r\\n             GVHD is permitted.)\\r\\n\\r\\n          -  Subjects who received systemic anticancer therapy or radiotherapy <14 days prior to\\r\\n             their first day of study drug administration. (Hydroxyurea is allowed prior to\\r\\n             enrollment and after the start of AG-120).\\r\\n\\r\\n          -  Subjects who received an investigational agent <14 days prior to their first day of\\r\\n             study drug administration.\\r\\n\\r\\n          -  Subjects who are pregnant or breastfeeding.\\r\\n\\r\\n          -  Subjects with an active severe infection or with an unexplained fever >38.5°C during\\r\\n             screening visits or on their first day of study drug administration (at the discretion\\r\\n             of the Investigator, subjects with tumor fever may be enrolled).\\r\\n\\r\\n          -  Subjects with New York Heart Association (NYHA) Class III or IV congestive heart\\r\\n             failure or LVEF <40% by echocardiogram (ECHO) or multi-gated acquisition (MUGA) scan\\r\\n             within approximately 28 days of C1D1.\\r\\n\\r\\n          -  Subjects with a history of myocardial infarction within the last 6 months of\\r\\n             screening.\\r\\n\\r\\n          -  Subjects with a known unstable or uncontrolled angina pectoris.\\r\\n\\r\\n          -  Subjects with a known history of severe and/or uncontrolled ventricular arrhythmias.\\r\\n\\r\\n          -  Subjects with known unstable or uncontrolled angina pectoris.\\r\\n\\r\\n          -  Subjects with heart-rate corrected QT (QTc) interval ≥450 ms or other factors that\\r\\n             increase the risk of QT prolongation or arrhythmic events.\\r\\n\\r\\n          -  Patients taking medications that are known to prolong the QT interval\\r\\n\\r\\n          -  Subjects with known infection with human immunodeficiency virus (HIV) or active\\r\\n             hepatitis B or C.\\r\\n\\r\\n          -  Subjects with clinical symptoms suggesting active central nervous system (CNS)\\r\\n             leukemia or known CNS leukemia. Evaluation of cerebrospinal fluid is only required if\\r\\n             there is a clinical suspicion of CNS involvement by leukemia during screening.\\r\\n\\r\\n          -  Subjects with immediately life-threatening, severe complications of leukemia such as\\r\\n             uncontrolled bleeding, pneumonia with hypoxia or shock, and/or disseminated\\r\\n             intravascular coagulation.\\r\\n      \\nAI: \\nTool: false\\nAI: \\nTool: 2025-07-20\\nAI: \\nTool: year: 2025, month: 7\"\n",
      "  ]\n",
      "}\n",
      "\u001b[36;1m\u001b[1;3m[llm/end]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent > chain:call_model > chain:RunnableSequence > llm:ChatGroq] [364ms] Exiting LLM run with output:\n",
      "\u001b[0m{\n",
      "  \"generations\": [\n",
      "    [\n",
      "      {\n",
      "        \"text\": \"no \\n\",\n",
      "        \"generation_info\": {\n",
      "          \"finish_reason\": \"stop\",\n",
      "          \"logprobs\": null\n",
      "        },\n",
      "        \"type\": \"ChatGeneration\",\n",
      "        \"message\": {\n",
      "          \"lc\": 1,\n",
      "          \"type\": \"constructor\",\n",
      "          \"id\": [\n",
      "            \"langchain\",\n",
      "            \"schema\",\n",
      "            \"messages\",\n",
      "            \"AIMessage\"\n",
      "          ],\n",
      "          \"kwargs\": {\n",
      "            \"content\": \"no \\n\",\n",
      "            \"response_metadata\": {\n",
      "              \"token_usage\": {\n",
      "                \"completion_tokens\": 5,\n",
      "                \"prompt_tokens\": 3049,\n",
      "                \"total_tokens\": 3054,\n",
      "                \"completion_time\": 0.009090909,\n",
      "                \"prompt_time\": 0.056961326,\n",
      "                \"queue_time\": 0.19678364299999998,\n",
      "                \"total_time\": 0.066052235\n",
      "              },\n",
      "              \"model_name\": \"gemma2-9b-it\",\n",
      "              \"system_fingerprint\": \"fp_10c08bf97d\",\n",
      "              \"service_tier\": \"on_demand\",\n",
      "              \"finish_reason\": \"stop\",\n",
      "              \"logprobs\": null\n",
      "            },\n",
      "            \"type\": \"ai\",\n",
      "            \"id\": \"run--19344250-fca3-4acb-bde0-3304235520d6-0\",\n",
      "            \"usage_metadata\": {\n",
      "              \"input_tokens\": 3049,\n",
      "              \"output_tokens\": 5,\n",
      "              \"total_tokens\": 3054\n",
      "            },\n",
      "            \"tool_calls\": [],\n",
      "            \"invalid_tool_calls\": []\n",
      "          }\n",
      "        }\n",
      "      }\n",
      "    ]\n",
      "  ],\n",
      "  \"llm_output\": {\n",
      "    \"token_usage\": {\n",
      "      \"completion_tokens\": 5,\n",
      "      \"prompt_tokens\": 3049,\n",
      "      \"total_tokens\": 3054,\n",
      "      \"completion_time\": 0.009090909,\n",
      "      \"prompt_time\": 0.056961326,\n",
      "      \"queue_time\": 0.19678364299999998,\n",
      "      \"total_time\": 0.066052235\n",
      "    },\n",
      "    \"model_name\": \"gemma2-9b-it\",\n",
      "    \"system_fingerprint\": \"fp_10c08bf97d\",\n",
      "    \"service_tier\": \"on_demand\"\n",
      "  },\n",
      "  \"run\": null,\n",
      "  \"type\": \"LLMResult\"\n",
      "}\n",
      "\u001b[36;1m\u001b[1;3m[chain/end]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent > chain:call_model > chain:RunnableSequence] [366ms] Exiting Chain run with output:\n",
      "\u001b[0m[outputs]\n",
      "\u001b[36;1m\u001b[1;3m[chain/end]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent > chain:call_model] [367ms] Exiting Chain run with output:\n",
      "\u001b[0m[outputs]\n",
      "\u001b[32;1m\u001b[1;3m[chain/start]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent > chain:should_continue] Entering Chain run with input:\n",
      "\u001b[0m[inputs]\n",
      "\u001b[36;1m\u001b[1;3m[chain/end]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent > chain:should_continue] [1ms] Exiting Chain run with output:\n",
      "\u001b[0m{\n",
      "  \"output\": \"__end__\"\n",
      "}\n",
      "\u001b[36;1m\u001b[1;3m[chain/end]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent] [369ms] Exiting Chain run with output:\n",
      "\u001b[0m[outputs]\n",
      "\u001b[36;1m\u001b[1;3m[chain/end]\u001b[0m \u001b[1m[chain:LangGraph] [1.71s] Exiting Chain run with output:\n",
      "\u001b[0m[outputs]\n",
      "'no \\n'\n"
     ]
    }
   ],
   "source": [
    "# sample policy evaluation\n",
    "import langchain\n",
    "langchain.debug = True\n",
    "policy = docs_retrieved[0].page_content\n",
    "# nprint(policy)\n",
    "result = policy_tools(policy, patient_profile, model_agent)\n",
    "nprint(result)\n",
    "langchain.debug = False"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Trials Retriever \n",
    "\n",
    "We use SelfQueryRetriever module that also uses metadata information. This retrival can quickly find relevant trials based on metadata such as disease category, drug names, etc.   \n",
    "The value of such retrival becomes important for real applications, where patient profiles contain more comphrehensive medical histories."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Number of trials in the vector store: 18\n"
     ]
    }
   ],
   "source": [
    "from langchain.chains.query_constructor.base import AttributeInfo\n",
    "from langchain.retrievers.self_query.base import SelfQueryRetriever\n",
    "\n",
    "print(f\"Number of trials in the vector store: {vectorstore_trials._collection.count()}\")\n",
    "        \n",
    "metadata_field_info = [\n",
    "    AttributeInfo(\n",
    "        name=\"disease_category\",\n",
    "        description=\"Defines the disease group of patients related to this trial. One of ['cancer', 'leukemia', 'mental_health']\",\n",
    "        # description=\"The trial is for patients when their disease is related to this category. One of ['cancer', 'leukemia', 'mental_health']\",\n",
    "        type=\"string\",\n",
    "    ),\n",
    "    AttributeInfo(\n",
    "        name=\"drugs\",\n",
    "        description=\"List of drug names used in the trial\",\n",
    "        type=\"str\",\n",
    "    ),    \n",
    "]\n",
    "\n",
    "document_content_description = \"The list of patient conditions to include or exclude them from the trial\"\n",
    "retriever_trial_sq = SelfQueryRetriever.from_llm(\n",
    "    model,\n",
    "    vectorstore_trials,\n",
    "    # vectorstore_trials_mpnet,\n",
    "    document_content_description,\n",
    "    metadata_field_info\n",
    "    # enable_limit=True\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Embedding texts: 100%|██████████| 1/1 [00:00<00:00, 30.49inputs/s]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'disease_category': 'cancer', 'nctid': 'NCT01485861', 'drugs': \"['abiraterone', 'apitolisib', 'ipatasertib', 'placebo', 'prednisone', 'prednisolone']\", 'diseases': \"['prostate cancer']\", 'status': 'recruiting'}\n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Histologically confirmed metastatic or advanced prostate adenocarcinoma that has been\n",
      "             previously treated with docetaxel-based therapy and has progressed during treatment of\n",
      "             at least one hormonal therapy(prior docetaxel is not required for the safety cohort)\n",
      "\n",
      "          -  Two rising PSA levels greater than or equal to (>/=) 2 ng/mL measured >/= 1 week apart\n",
      "             or radiographic evidence of disease progression in soft tissue or bone\n",
      "\n",
      "          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at screening\n",
      "\n",
      "          -  Adequate hematologic and organ function\n",
      "\n",
      "          -  Documented willingness to use an effective means of contraception\n",
      "\n",
      "          -  Safety cohort only: agreement to use CGM for first cycle of treatment\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  History of Type I or Type II diabetes mellitus requiring insulin; safety cohort:\n",
      "             patients who are receiving any pharmacologic treatment for diabetes are not eligible\n",
      "\n",
      "          -  New York Heart Association Class III or IV heart failure or Left ventricular ejection\n",
      "             fraction < 50% or ventricular arrhythmia requiring medication\n",
      "\n",
      "          -  Significant atherosclerotic disease, as evidenced by: unstable angina, history of\n",
      "             myocardial infarction within 6 months prior to Day 1, or cerebrovascular accident\n",
      "             within 6 months prior to Day 1\n",
      "\n",
      "          -  Active autoimmune disease that is not controlled by nonsteroidal anti-inflammatory\n",
      "             drugs or active inflammatory disease which requires immunosuppressive therapy\n",
      "\n",
      "          -  Clinically significant history of liver disease\n",
      "\n",
      "          -  History of adrenal insufficiency or hyperaldosteronism\n",
      "\n",
      "          -  Phase II only: Previous therapy for prostate cancer with 17\n",
      "             alpha-hydroxylase/C17,20-lyase inhibitors, including abiraterone\n",
      "\n",
      "          -  Phase II only: Previous treatment for prostate cancer with Protein kinase B\n",
      "             phosphatidylinositol 3 kinase and/or mammalian target of rapamycin inhibitors\n",
      "\n",
      "          -  Need for chronic corticosteroid therapy of >/= 20 mg of prednisone per day or an\n",
      "             equivalent dose of other anti inflammatory corticosteroids or immunosuppressant\n",
      "      \n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\n"
     ]
    }
   ],
   "source": [
    "# sample trial retrieval\n",
    "question = f\"\"\"\n",
    "Which trials are relevant to the patient with the following medical history?\\n\n",
    "patient_profile: {patient_profile}\n",
    "\"\"\"        \n",
    "docs_retrieved = retriever_trial_sq.get_relevant_documents(question)\n",
    "print(docs_retrieved[0].metadata)\n",
    "print(docs_retrieved[0].page_content)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Trial Grader\n",
    "\n",
    "Each retrieved trial is checked for relevance to the patient's medical profile. The final output would be in the form of a binary relevance score, the explanation behind the score, and further information that is needed from the patient's medical history."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {},
   "outputs": [],
   "source": [
    "class grade(BaseModel):\n",
    "        \"\"\"The result of the trial's relevance check as relevance score and explanation.\"\"\"\n",
    "\n",
    "        relevance_score: str        \n",
    "        explanation: str = Field(description=\"Reasons to the given relevance score.\")        \n",
    "        further_information: str\n",
    "\n",
    "prompt_grader = PromptTemplate(\n",
    "        template=\"\"\" \n",
    "        You are a Principal Investigator (PI) for evaluating patients for clinical trials.\\n\n",
    "        Your task is to evaluate the relevance of a clinical trial to the given patient's medical profile. \\n\n",
    "        \n",
    "        \n",
    "        The clinical trial is related to these diseases: {trial_diseases} \\n\n",
    "        Here are the inclusion and exclusion criteria of the trial: \\n\\n {document} \\n\\n\n",
    "        \n",
    "        ===============                \n",
    "        Use the following steps to determine relevance and provide the necessary fields in your response: \\n\n",
    "        1- If the patient's profile meets any exclusion criteria, then the trial is not relevant --> relevance_score = 'No'. \\n\n",
    "        2- If the patient has or had the trial's inclusion diseases, then it is relevant --> relevance_score = 'Yes'.\\n        \n",
    "        3- If the patient did not have the trial's inclusion diseases, then it is not relevant --> relevance_score = 'No'.\\n\n",
    "                       \n",
    "        Example 1: \n",
    "The patient has Arthritis and the trial is related to pancreatic cancer. --> relevance_score = 'No' \\n\n",
    "        \n",
    "        Example 2: \n",
    "The patient has pancreatic cancer and the trial is also related to carcinoma pancreatic cancer. --> relevance_score = 'Yes' \\n\n",
    "\n",
    "        Example 3: \n",
    "The patient has pancreatic cancer and the trial is related to breast cancer or ovarian cancer. --> relevance_score = 'No'. \\n \n",
    "\n",
    "        Bring your justification in the explanation. \\n\n",
    "\n",
    "        Mention further information that is needed from the patient's medical history related to the trial's criteria \\n\n",
    "\n",
    "        ===============\n",
    "        Here is the patient's medical profile: {patient_profile} \\n\\n\n",
    "        \"\"\",\n",
    "        input_variables=[\"document\", \"patient_profile\", \"trial_diseases\"],\n",
    "    )\n",
    "\n",
    "llm_with_tool = model.with_structured_output(grade)\n",
    "retrieval_grader = prompt_grader | llm_with_tool"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "('relevance_score', 'No')\n",
      "( 'explanation',\n",
      "  \"The patient's medical profile does not indicate if they have prostate \"\n",
      "  'cancer, a requirement for this trial.  Further information is needed '\n",
      "  \"regarding the patient's history of prostate cancer.\")\n",
      "( 'further_information',\n",
      "  'It is necessary to know if the patient has a history of prostate cancer to '\n",
      "  'determine eligibility for this trial.')\n"
     ]
    }
   ],
   "source": [
    "doc = docs_retrieved[0]\n",
    "doc_txt = doc.page_content\n",
    "trial_diseases = doc.metadata.get(\"diseases\")\n",
    "trial_score = retrieval_grader.invoke({\"patient_profile\": patient_profile, \"document\": doc_txt, \"trial_diseases\": trial_diseases})\n",
    "\n",
    "for score in trial_score:\n",
    "    nprint(score)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Hallucination Grader\n",
    "When agent cross-matches the patient's medical profile, it sometimes relates the input information (patient profile or trial data) to its trained knowledge. Or in some cases it makes non-existing assumptions about the patient's medical history.\n",
    "   \n",
    "These cases, known as llm hallucinations, can be prevented by cross-matching the input information with the model's completion. We created a guardrail using this strategy.\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "No\n",
      "(\"The patient's medical profile does not indicate if they have prostate \"\n",
      " 'cancer, a requirement for this trial.  Further information is needed '\n",
      " \"regarding the patient's history of prostate cancer.\")\n",
      "no\n",
      "(\"The LLM states the patient's profile does not indicate prostate cancer, \"\n",
      " 'which is a requirement for a trial, but the profile does not mention '\n",
      " 'prostate cancer.')\n"
     ]
    }
   ],
   "source": [
    "class GradeHallucinations(BaseModel):\n",
    "    \"\"\"Binary score and explanation for whether the LLM's generated answer is grounded in / supported by the facts in the patient's medical profile.\"\"\"\n",
    "    # \"\"\"Binary score for hallucination present in generation answer.\"\"\"\n",
    "\n",
    "\n",
    "    binary_score: str = Field(\n",
    "        description=\"Answer is grounded in the patient's medical profile, 'yes' or 'no'\"\n",
    "    )\n",
    "    Reason: str = Field(description=\"Reasons to the given relevance score.\")\n",
    "\n",
    "\n",
    "# LLM with function call\n",
    "llm_with_tool = model.with_structured_output(GradeHallucinations)\n",
    "\n",
    "# Prompt\n",
    "system = \"\"\"You are a grader assessing whether an LLM generation is grounded in / supported by the facts in the patient's medical profile. \\n \n",
    "     Give a binary score 'yes' or 'no'. 'Yes' means that the answer is grounded in / supported by the facts in the patient's medical profile.\"\"\"\n",
    "hallucination_prompt = ChatPromptTemplate.from_messages(\n",
    "    [\n",
    "        (\"system\", system),\n",
    "        (\"human\", \"Patient's medical profile: \\n\\n {patient_profile} \\n\\n LLM generation: {explanation}\"),\n",
    "    ]\n",
    ")\n",
    "\n",
    "hallucination_grader = hallucination_prompt | llm_with_tool\n",
    "print(trial_score.relevance_score)\n",
    "explanation = trial_score.explanation\n",
    "nprint(explanation)\n",
    "# docs = patient_profile\n",
    "score = hallucination_grader.invoke({\"patient_profile\": patient_profile, \"explanation\": explanation})\n",
    "grade = score.binary_score\n",
    "print(grade)\n",
    "nprint(score.Reason)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Profile Rewriter\n",
    "\n",
    "In some cases, which is often the case in this demo, the patient's medical history is not complete or does not directly indicate relevant clinical trials. However, there could still be a connecton between its disease(s) and some of the trial descriptions. Therefore, Insread of manually rewriting the patient's medical history, we can use the LLM to extpand the trial suggetions in their profile. This can also be used as a draft for a clinical specialist to further complete the patient's profile.\n",
    "\n",
    "The Profile Rewriter is an llm based tool that tries to link the patient's medical history to a predefined set of clinical categories."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'The patient is a 72-year-old with a medical history of Hypertension. They have not participated in any previous trials. \\n\\nSuggested relevant trials: \\nThere are no suggested trials as the provided information does not indicate any diseases that would typically be relevant to cancer, leukemia, or mental health trials. \\n'"
      ]
     },
     "execution_count": 25,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "system = \"\"\"\n",
    "A trial cross match resulted in no trials for the patient.\n",
    "As a clinical specialist write a medical profile for this patient and see if their disease(s) can be relevant to any of these categories of mental_health, cancer, or leukemia.\n",
    "If yes, then suggest relevant medical trial categories for the agent.\n",
    "If no, then do not add anything there.\n",
    "\n",
    "Your output must be as below:\n",
    "<a text summart of original profile>\n",
    "Suggested relevant trials:\n",
    "<bullet points of relevant medical trial categoriyes from the above with a one line reason>\n",
    "\n",
    "Only include categories which can be related to patient diseases in more often cases.\n",
    "Disregard categories which ocasionaly or in some cases can be relevant to patient diseases.\n",
    "\n",
    "example:\n",
    "The patient is a X-year-old with a medical history of Y. They have participated ........  previous trials, and their trial status and completion date .........\n",
    "Suggested relevant trials:\n",
    "category X: [patient's disease] can be related to X due to Y.\n",
    "\"\"\"\n",
    "re_write_prompt = ChatPromptTemplate.from_messages(\n",
    "    [\n",
    "        (\"system\", system),\n",
    "        (\n",
    "            \"human\",\n",
    "            \"Here is a patient data:\\n\\n {patient_data} \\n write a patient profile.\",\n",
    "        ),\n",
    "    ]\n",
    ")\n",
    "\n",
    "profile_rewriter_chain = re_write_prompt | model | StrOutputParser()\n",
    "profile_rewriter_chain.invoke({\"patient_data\": patient_data})"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Graph\n",
    "To implement the pipeline of extracting and evaluating the patient's information and clinical policies and trials, we use [LangGraph](https://langchain-ai.github.io/langgraph/).   \n",
    "This is a comprehensive tool-chain for creating agent-based pipelines in Langchain. \n",
    "The main two components are:\n",
    "- Agent state\n",
    "- Agent graph\n",
    "  \n",
    "Following their [tutorials](https://langchain-ai.github.io/langgraph/tutorials/), you can create many different agentic designs with Langgraph. Even for the same applications you may create different graph architectures."
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## State\n",
    "To help agent (and also us) to keep track of the state of information in the graph, we define an agent state and its relevant values.   \n",
    "These values are passed from one node of the graph to the other or will be modified during iterations."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "metadata": {},
   "outputs": [],
   "source": [
    "from typing import Annotated, List\n",
    "from typing_extensions import TypedDict\n",
    "from langgraph.graph.message import AnyMessage, add_messages\n",
    "from langchain_core.messages import AIMessage, SystemMessage, HumanMessage, ToolMessage\n",
    "from langchain_core.documents import Document\n",
    "\n",
    "class AgentState(TypedDict):\n",
    "    # messages: Annotated[Sequence[BaseMessage], operator.add]\n",
    "    last_node: str\n",
    "    patient_prompt: str\n",
    "    patient_id: int\n",
    "    patient_data: dict\n",
    "    patient_profile: str\n",
    "    policy_eligible: bool\n",
    "    policies: List[Document]\n",
    "    checked_policy: Document\n",
    "    unchecked_policies: List[Document]\n",
    "    policy_qs: str\n",
    "    rejection_reason: str    \n",
    "    revision_number: int\n",
    "    max_revisions: int\n",
    "    trial_searches: int\n",
    "    max_trial_searches: int            \n",
    "    trials: List[Document]\n",
    "    relevant_trials: list[dict]\n",
    "    ask_expert: str"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Agent\n",
    "The main Agent graph is defined by nodes and edges. Nodes are the main steps of the pipeline, and edges define the transitions between the nodes (steps).\n",
    "\n",
    "In our architecture, the steps of the pipeline are most of the time deterministic. We also tried to define nodes of the graph according to the main steps of the clinical evaluation pipeline. This helps you to follow the logics and steps easier. \n",
    "  \n",
    "However, you can also use a single centric assistant node and let the agent to decide which tool must be called given the current state in the process. This may look more professional, but needs more effort to built robustly."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<langgraph.graph.state.StateGraph at 0x147e41f40>"
      ]
     },
     "execution_count": 27,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "from langgraph.checkpoint.sqlite import SqliteSaver\n",
    "from langgraph.prebuilt import ToolNode\n",
    "from langgraph.prebuilt import tools_condition\n",
    "from langchain_core.pydantic_v1 import BaseModel, Field\n",
    "from operator import itemgetter\n",
    "from typing import Literal\n",
    "from langgraph.graph import StateGraph, END\n",
    "\n",
    "\n",
    "# model = ChatOpenAI(model=modelID)  #reduce inference cost\n",
    "\n",
    "\n",
    "\n",
    "class Patient_ID(BaseModel):\n",
    "    patient_id: int\n",
    "    # no_id: bool\n",
    "\n",
    "def patient_collector_node(state: AgentState):\n",
    "    patient_data_prompt = \"\"\"You are a helpful assistance in extrcting patient's medical history.\n",
    "Based on the following request identify and return the patient's ID number.\n",
    "\"\"\"\n",
    "\n",
    "    response = model.with_structured_output(Patient_ID).invoke([\n",
    "        SystemMessage(content=patient_data_prompt),\n",
    "        HumanMessage(content=state['patient_prompt'])\n",
    "    ])\n",
    "    patient_id = response.patient_id\n",
    "    # print(response)\n",
    "    print(f\"Patient ID: {patient_id}\")\n",
    "    patient_data = get_patient_data(patient_id)\n",
    "    print(patient_data)\n",
    "    if patient_data is not None:        \n",
    "        if patient_data.get('name'):\n",
    "            del patient_data['patient_id']\n",
    "            del patient_data['name']\n",
    "        patient_profile = chain_profile.invoke({'patient_data': patient_data})\n",
    "\n",
    "    return {\n",
    "        \"last_node\": \"patient_collector\",\n",
    "        \"patient_data\": patient_data,\n",
    "        \"patient_profile\": patient_profile,\n",
    "        \"patient_id\": patient_id,\n",
    "        \"revision_number\": state.get(\"revision_number\", 1) + 1,\n",
    "        'policy_eligible': 'N/A'\n",
    "        }\n",
    "\n",
    "def policy_search(state: AgentState) -> List[Document]:    \n",
    "    # question = f\"\"\"\n",
    "    # Does the following patient profile comply with the institutional policies?\\n\n",
    "    # {patient_profile}\n",
    "    # \"\"\"\n",
    "    docs_retrieved = retriever_policy.get_relevant_documents(patient_profile)    \n",
    "    return {\n",
    "        \"last_node\": \"policy_search\",\n",
    "        \"policies\": docs_retrieved,\n",
    "        \"unchecked_policies\": docs_retrieved.copy(),\n",
    "    }\n",
    "\n",
    "def policy_evaluator(state: AgentState, policy_doc: Document = None, model_agent=model_agent):\n",
    "    if policy_doc is None:\n",
    "        policy_doc = state['unchecked_policies'][0]\n",
    "    \n",
    "    policy_header = policy_doc.page_content.split('\\n', 2)[1]\n",
    "    print(f'Evaluating Policy:\\n {policy_header}')\n",
    "    \n",
    "    policy = policy_doc.page_content\n",
    "    \n",
    "    policy_qs = policy_rps_chain.invoke({\"policy\": policy})\n",
    "    \n",
    "    # result = policy_repl(policy_qs, state['patient_profile'])\n",
    "    result = policy_tools(policy_qs, state['patient_profile'], model_agent)\n",
    "    # nprint(result['output'])\n",
    "\n",
    "    class eligibility(BaseModel):\n",
    "        \"\"\" Give the patient's eligibility result.\"\"\"\n",
    "\n",
    "        eligibility: str = Field(description=\"Patient's eligibility for the clinical trial. 'yes' or 'no'\")\n",
    "        reason: str = Field(description=\"The reason(s) only if the patient is not eligible for clinical trials. Othereise use N/A\")\n",
    "\n",
    "        class Config:\n",
    "            schema_extra = {\n",
    "                \"example\": {\n",
    "                    \"eligibility\": 'yes',\n",
    "                    \"reason\": \"N/A\",\n",
    "                },\n",
    "                \"example 2\": {\n",
    "                    \"eligibility\": 'no',\n",
    "                    \"reason\": \"The patient is pregnant at the moment.\",\n",
    "                },                \n",
    "            }\n",
    "\n",
    "    llm_with_tools = model.bind_tools([eligibility])\n",
    "    message = f\"\"\"Evaluation of the patient's eligibility:\n",
    "    {result}\\n\\n\n",
    "    Is the patient eligible according to this policy?\"\"\"\n",
    "    response = llm_with_tools.invoke(message)\n",
    "    policy_eligible = response.tool_calls[0]['args']['eligibility']             \n",
    "\n",
    "    state[\"policy_eligible\"] = policy_eligible.lower() == 'yes'\n",
    "    state[\"rejection_reason\"] = response.tool_calls[0]['args']['reason']\n",
    "    \n",
    "    # remove the first element of unchecked_policies\n",
    "    state['unchecked_policies'].pop(0)\n",
    "    state[\"revision_number\"] = state.get(\"revision_number\", 1) + 1\n",
    "    state['checked_policy'] = policy_doc\n",
    "    state['policy_qs'] = policy_qs\n",
    "    state['last_node'] = 'policy_evaluator'\n",
    "\n",
    "    return state\n",
    "\n",
    "def trial_search(state: AgentState):\n",
    "    \"\"\"\n",
    "    This node searches the trial database to retrieve a list of clinical trials that match the patient's medical history.\n",
    "    \"\"\"\n",
    "\n",
    "    patient_profile = state['patient_profile']\n",
    "\n",
    "    question = f\"\"\"\n",
    "    Which trials are relevant to the patient with the following medical history?\\n\n",
    "    patient_profile: {patient_profile}\n",
    "    \"\"\"        \n",
    "    docs_retrieved = retriever_trial_sq.get_relevant_documents(question)\n",
    "    # print(state)\n",
    "    trial_searches = state.get('trial_searches') or 0\n",
    "    return {\n",
    "        'last_node': 'trial_search',\n",
    "        'trials': docs_retrieved,\n",
    "        'trial_searches': trial_searches + 1,\n",
    "        }\n",
    "\n",
    "def grade_trials(state: AgentState, trials: List[Document] = None):\n",
    "    \"\"\"\n",
    "    Determines whether the retrieved documents are relevant to the question.\n",
    "\n",
    "    Args:\n",
    "        state (dict): The current graph state\n",
    "\n",
    "    Returns:\n",
    "        state (dict): Updates documents key with only filtered relevant documents\n",
    "    \"\"\"\n",
    "\n",
    "    print(\"----- CHECKING THE TRIALS RELEVANCE TO PATIENT PROFILE ----- \")\n",
    "    \n",
    "    if trials is None:\n",
    "        trials = state['trials']\n",
    "    patient_profile = state['patient_profile']\n",
    "\n",
    "    # Score each doc\n",
    "    relevant_trials = []\n",
    "    for trial in trials:\n",
    "        doc_txt = trial.page_content\n",
    "        trial_diseases = trial.metadata['diseases']\n",
    "        nctid = trial.metadata['nctid']\n",
    "        print(f\"---GRADER: TRIAL {nctid}: ---\") \n",
    "        trial_score = retrieval_grader.invoke(\n",
    "            {\n",
    "                \"patient_profile\": patient_profile, \n",
    "                \"document\": doc_txt, \n",
    "                \"trial_diseases\": trial_diseases\n",
    "            }\n",
    "        )\n",
    "            \n",
    "        relevance_score = trial_score.relevance_score\n",
    "        trial_score_dic = dict(trial_score)\n",
    "        trial_score_dic['nctid'] = nctid                    \n",
    "\n",
    "        if relevance_score.lower() == \"yes\":   \n",
    "            # Hullucination check         \n",
    "            explanation = trial_score.explanation            \n",
    "            factual_score = hallucination_grader.invoke({\"patient_profile\": patient_profile, \"explanation\": explanation})\n",
    "            factual_score_grade = factual_score.binary_score            \n",
    "            if factual_score_grade == \"no\":\n",
    "                print(\"--- HALLUCINATION: MODEL'S EXPLANATION IS NOT GROUNDED IN PATIENT PROFILE --> REJECTED---\")\n",
    "                trial_score_dic['relevance_score'] = 'no'\n",
    "                trial_score_dic['explanation'] = \"Agent's Hallucination\"\n",
    "\n",
    "        if relevance_score.lower() == \"yes\" and factual_score_grade == \"yes\":\n",
    "            print(f\"---TRIAL RELEVANT---\")                        \n",
    "        else:\n",
    "            print(f\"--- TRIAL NOT RELEVANT---\")\n",
    "\n",
    "        relevant_trials.append(trial_score_dic)\n",
    "        \n",
    "    return {\n",
    "        'last_node': 'grade_trials',\n",
    "        \"relevant_trials\": relevant_trials\n",
    "        }\n",
    "\n",
    "def profile_rewriter(state: AgentState):\n",
    "    patient_data = state['patient_data']\n",
    "    patient_profile_rewriten = profile_rewriter_chain.invoke({\"patient_data\": patient_data})\n",
    "    # print in capitals\n",
    "    print(\"--- PROFILE REWRITER: PATIENT'S PROFILE REWRITEN ---\")\n",
    "    # state['patient_profile'] = patient_profile_rewriten\n",
    "    return {\n",
    "        'last_node': 'profile_rewriter',\n",
    "        'patient_profile': patient_profile_rewriten\n",
    "    }\n",
    "    \n",
    "\n",
    "# ========= continue functions =========\n",
    "def should_continue_patient(state: AgentState):\n",
    "    # end = False\n",
    "    if state.get(\"patient_data\"):\n",
    "        # print('patient data found')\n",
    "        print(state.get(\"patient_profile\", 'No profile generated'))\n",
    "        return \"policy_search\"\n",
    "    else:\n",
    "        print('Patient data not found in the database')\n",
    "        return END\n",
    "        \n",
    "    if state[\"revision_number\"] > state[\"max_revisions\"]:\n",
    "        print('max revision reached')\n",
    "        # print(state.get(\"patient_data\", 1))\n",
    "        return END        \n",
    "\n",
    "def should_continue_policy(state: AgentState):\n",
    "    if state[\"revision_number\"] > state[\"max_revisions\"]:\n",
    "        print('max revision reached')        \n",
    "        return END\n",
    "    more_policies = len(state[\"unchecked_policies\"]) > 0\n",
    "    if state[\"policy_eligible\"]:\n",
    "        if more_policies:\n",
    "            print(\"-------------- Check the next policy --------------\")\n",
    "            return \"policy_evaluator\"\n",
    "        else:\n",
    "            print(\"-------------- Patient passed the general trials policies --------------\")\n",
    "            return \"trial_search\"\n",
    "    else:\n",
    "        print(\"Patient did not pass this policy.\\n\")\n",
    "        print(state['checked_policy'].page_content)\n",
    "        # print(\"Patient did not pass the general trials policies.\\n\")        \n",
    "        print('Rejection Reason: ')\n",
    "        nprint(state['rejection_reason'])\n",
    "        print(\"You can correct the patient's medical profile if required.\")        \n",
    "        return END\n",
    "\n",
    "def should_continue_trials(state: AgentState):\n",
    "    relevant_trials = state[\"relevant_trials\"]    \n",
    "    has_relevant_trial = any(trial['relevance_score'] == 'Yes' for trial in state[\"relevant_trials\"])\n",
    "\n",
    "    if state[\"trial_searches\"] > state[\"max_trial_searches\"]:\n",
    "        print('max trial searches reached')\n",
    "        next = END    \n",
    "    # elif not state[\"relevant_trials\"]:\n",
    "    elif has_relevant_trial == False:\n",
    "        print('----- No relevant trials found --> rewriting the patient profile -----')\n",
    "        next = \"profile_rewriter\"        \n",
    "    else:\n",
    "        next = END\n",
    "        print('to end')\n",
    "    return next\n",
    "\n",
    "\n",
    "# ==== define graph nodes====\n",
    "builder = StateGraph(AgentState)\n",
    "builder.set_entry_point(\"patient_collector\")\n",
    "builder.add_node(\"patient_collector\", patient_collector_node)\n",
    "builder.add_node(\"policy_search\", policy_search)\n",
    "builder.add_node(\"policy_evaluator\", policy_evaluator)\n",
    "builder.add_node(\"trial_search\", trial_search)\n",
    "builder.add_node(\"grade_trials\", grade_trials)\n",
    "builder.add_node(\"profile_rewriter\", profile_rewriter)\n",
    "\n",
    "# ===== define graph edges====\n",
    "builder.add_conditional_edges(\n",
    "    \"patient_collector\", \n",
    "    should_continue_patient, \n",
    "    {END: END    \n",
    "    ,\"policy_search\": \"policy_search\"\n",
    "    }\n",
    ")\n",
    "\n",
    "builder.add_conditional_edges(\n",
    "    \"policy_evaluator\", \n",
    "    should_continue_policy, \n",
    "    {\n",
    "    \"trial_search\": \"trial_search\"\n",
    "    , \"policy_evaluator\": \"policy_evaluator\"\n",
    "    , END: END\n",
    "    }\n",
    ")\n",
    "\n",
    "builder.add_edge(\"policy_search\", \"policy_evaluator\")\n",
    "builder.add_edge(\"trial_search\", \"grade_trials\")\n",
    "builder.add_edge(\"profile_rewriter\",\"trial_search\")\n",
    "# builder.set_finish_point(\"grade_trials\")\n",
    "\n",
    "builder.add_conditional_edges(\n",
    "    \"grade_trials\", \n",
    "    should_continue_trials, \n",
    "    {\n",
    "    \"profile_rewriter\": \"profile_rewriter\"    \n",
    "    , END: END\n",
    "    }\n",
    ")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Initiate the graph"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<IPython.core.display.Image object>"
      ]
     },
     "execution_count": 28,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "from langgraph.checkpoint.sqlite import SqliteSaver\n",
    "from helper_functions import create_workflow_builder, create_agent_state\n",
    "\n",
    "conn = sqlite3.connect(\"checkpoints.sqlite\", check_same_thread=False)\n",
    "memory = SqliteSaver(conn)\n",
    "\n",
    "# from langgraph.checkpoint.memory import InMemorySaver\n",
    "# memory = InMemorySaver()\n",
    "\n",
    "agent_state = create_agent_state()\n",
    "builder = create_workflow_builder(agent_state)\n",
    "\n",
    "graph = builder.compile(\n",
    "    checkpointer=memory\n",
    ")\n",
    "\n",
    "from IPython.display import Image\n",
    "\n",
    "Image(graph.get_graph().draw_png())"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Invoke the Graph with no GUI:\n",
    "You can invoke the pipeline using the `stream` method. This is useful for debugging and the development phase.\n",
    "\n",
    "The thread variable acts like different graph run profiles.\n",
    "\n",
    "To use the LangGraph persistent and time travel capabilities, use the `resume_from_state` function from the `helper_functions` module.\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "metadata": {},
   "outputs": [],
   "source": [
    "import langchain\n",
    "langchain.debug = False\n",
    "sample_patient_id = 2\n",
    "thread = {\"configurable\": {\"thread_id\": \"0\"}}\n",
    "events_gen = graph.stream({\n",
    "    'patient_prompt': f\"Is patient {sample_patient_id} eligible for any medical trial?\",    \n",
    "    \"max_revisions\": 10,\n",
    "    \"revision_number\": 1,\n",
    "    'max_trial_searches':3,\n",
    "}, thread)\n",
    "\n",
    "if DEBUG == True:\n",
    "    for event in events_gen:\n",
    "        print(event)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Application GUI\n",
    "For the sake of quick development, a GUI is designed based on the `gradio` python package and an adoption from [This tutorial course](https://learn.deeplearning.ai/courses/ai-agents-in-langgraph). You can also use [streamlit](https://docs.streamlit.io/develop/tutorials/llms/build-conversational-apps) as another tool for GUI development.\n",
    "\n",
    "In the applicaiton, the process is interupted at several intermediate points using the `interrupt_after` argument. At these points, the user (the clinical expert) can decide whether to alter the patient's profile by adding or removing relevant/non-relevant information. The user can also skip some of rejections at these intrupt points to continue with the process.\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Closing server running on port: 7958\n",
      "* Running on local URL:  http://127.0.0.1:7958\n",
      "* To create a public link, set `share=True` in `launch()`.\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div><iframe src=\"http://127.0.0.1:7958/\" width=\"100%\" height=\"500\" allow=\"autoplay; camera; microphone; clipboard-read; clipboard-write;\" frameborder=\"0\" allowfullscreen></iframe></div>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/plain": []
     },
     "execution_count": 34,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import sys\n",
    "sys.path.insert(0, \"../frontend\")\n",
    "\n",
    "from helper_gui import trials_gui\n",
    "# from langgraph.checkpoint.memory import InMemorySaver\n",
    "# memory = InMemorySaver()\n",
    "\n",
    "conn = sqlite3.connect(\"checkpoints.sqlite\", check_same_thread=False)\n",
    "memory = SqliteSaver(conn)\n",
    "# memory = SqliteSaver.from_conn_string(\":memory:\")\n",
    "\n",
    "graph = builder.compile(\n",
    "    checkpointer=memory,\n",
    "    interrupt_after=['patient_collector', 'policy_search', 'trial_search', 'grade_trials', 'profile_rewriter']\n",
    "    # , interrupt_after=['grade_trials','profile_rewriter']\n",
    ")\n",
    "\n",
    "try:\n",
    "    app.demo.close()\n",
    "except:\n",
    "    print('initial run')\n",
    "app = trials_gui(graph)    \n",
    "app.demo.launch(server_name=\"127.0.0.1\", server_port=7958)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Possible Further Improvements for Real Application:\n",
    "\n",
    "To enhance the robustness of the pipeline and effectively manage diverse patient and trial conditions, it is essential to implement advanced methodologies, particularly when handling large databases of patients, trials, and policies.\n",
    "\n",
    "Recommended Improvements:\n",
    "1. Graph-Based Retrieval-Augmented Generation (RAG):\n",
    "- Implement graph-based RAG to focus on the relationships between entities across different databases. For instance, map connections between patients, diseases, drugs, and trials to provide more accurate and relevant information retrieval.\n",
    "\n",
    "2. Advanced RAG pipeline:\n",
    "- The output of RAG pipelines can be improved by benefiting from more advanced techniques such as Adaptive RAG, Corrective RAG, and Self-RAG. Such pipelines are more robust againts hallucinations and wrong inferences in LLMs outputs.\n",
    "\n",
    "4. Advanced Chain of Thought Processing:\n",
    "- Employ a more sophisticated chain of thought process to cross-match the patient's profile with the detailed information provided in each trial or policy. This approach enhances the decision-making capability of the system by considering multiple factors simultaneously.\n",
    "\n",
    "1. Fine-Tuning the Large Language Model:\n",
    "- Fine-tune the large language model using a diverse set of medical trial data to improve the accuracy and relevance of its inferences. This customization ensures the model better understands the nuances and specifics of clinical trial data.\n",
    "\n",
    "1. Cyclic Graphs for Iterative Evaluation:\n",
    "- Utilize cyclic graphs to iteratively evaluate the patient's profile against various trials and policies. This iterative approach allows the system to refine its matches through multiple rounds of evaluation, ultimately identifying the best possible trial for the patient."
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": ".lpenv",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.0"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
